



**Universiteit
Leiden**
The Netherlands

Carotid intima-media thickness progression as surrogate marker for cardiovascular risk meta-analysis of 119 clinical trials involving 100 667 patients

Willeit, P.; Tschiderer, L.; Allara, E.; Reuber, K.; Seekircher, L.; Gao, L.; ... ; PROG-IMT Proof-ATHERO Study Grp

Citation

Willeit, P., Tschiderer, L., Allara, E., Reuber, K., Seekircher, L., Gao, L., ... Lorenz, M. W. (2020). Carotid intima-media thickness progression as surrogate marker for cardiovascular risk meta-analysis of 119 clinical trials involving 100 667 patients. *Circulation*, 142(7), 621-642. doi:10.1161/CIRCULATIONAHA.120.046361

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3184874>

Note: To cite this publication please use the final published version (if applicable).



Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk

Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients

Editorial, see p 643

BACKGROUND: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk.

METHODS: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-artery; if unavailable, the maximum value at the common-carotid-artery or other cIMT measures were used. The primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. We estimated intervention effects on cIMT progression and incident CVD for each trial, before relating the 2 using a Bayesian meta-regression approach.

RESULTS: We analyzed data of 119 randomized, controlled trials involving 100 667 patients (mean age 62 years, 42% female). Over an average follow-up of 3.7 years, 12 038 patients developed the combined CVD end point. Across all interventions, each 10 $\mu\text{m}/\text{y}$ reduction of cIMT progression resulted in a relative risk for CVD of 0.91 (95% Credible Interval, 0.87–0.94), with an additional relative risk for CVD of 0.92 (0.87–0.97) being achieved independent of cIMT progression. Taken together, we estimated that interventions reducing cIMT progression by 10, 20, 30, or 40 $\mu\text{m}/\text{y}$ would yield relative risks of 0.84 (0.75–0.93), 0.76 (0.67–0.85), 0.69 (0.59–0.79), or 0.63 (0.52–0.74), respectively. Results were similar when grouping trials by type of intervention, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurement, and proportion of female patients.

CONCLUSIONS: The extent of intervention effects on cIMT progression predicted the degree of CVD risk reduction. This provides a missing link supporting the usefulness of cIMT progression as a surrogate marker for CVD risk in clinical trials.

Peter Willeit, MD, MPhil,
PhD*

Lena Tschiderer, DI, BSc,
PhD*

:

Michael J. Sweeting, PhD†
Simon G. Thompson, DSct
Matthias W. Lorenz, MD†
For the PROG-IMT and the
Proof-ATHERO Study
Groups

*Drs Willeit and Tschiderer contributed equally to this article.

†Drs Sweeting, Thompson, and Lorenz contributed equally to this article.

The full author list is available on page 634.

Key Words: cardiovascular disease
■ carotid intima-media thickness
■ clinical trials as topic ■ surrogate
marker ■ meta-analysis

Sources of Funding, see page 635

© 2020 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

Clinical Perspective

What Is New?

- We analyzed data of 119 randomized, controlled trials that involved 100 667 patients and 12 038 incident cardiovascular disease events.
- We used a Bayesian meta-regression approach to evaluate progression of carotid intima-media thickness as a surrogate marker for cardiovascular events.
- Our analysis revealed a statistically significant association between treatment effects on progression of carotid intima-media thickness and treatment effects on cardiovascular disease risk.

What Are the Clinical Implications?

- Our study provides the key missing link supporting the usefulness of carotid intima-media thickness progression as a surrogate marker for cardiovascular disease risk in clinical trials.
- Using progression of carotid intima-media thickness as a surrogate end point in future randomized, controlled trials may facilitate and speed up the development and licensing of new therapies.

Carotid intima-media thickness (cIMT), the thickness of the intimal and medial layer of the carotid artery wall, can be measured noninvasively using ultrasound imaging and is considered a marker for the early stage of atherosclerosis.¹ Mean values of cIMT in adults range around 650 to 900 μm and increase—on average—at a rate of 0 to 40 $\mu\text{m}/\text{y}$.^{2,3} A large number of randomized, controlled trials (RCTs) have demonstrated that therapeutic interventions may slow progression of cIMT. However, it is uncertain whether effects on cIMT progression translate into reduced risk of cardiovascular disease (CVD) events; that is, whether cIMT progression is a valid surrogate marker for CVD.

In 2005, Espeland et al first proposed cIMT progression as a surrogate marker for CVD risk on the basis of findings in 7 statin trials,⁴ but their arguments were based on limited data and most researchers were reluctant to rely on cIMT results alone.⁵ In 2009, ARBITER-6 HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) was the first RCT to be terminated early based on findings for cIMT progression, showing superiority of extended-release niacin over ezetimibe.⁶ This decision was controversial because of the uncertain validity of the rate of progression of cIMT as a surrogate marker for clinical end points.^{7,8} Two subsequent literature-based meta-regression analyses on this topic have yielded conflicting results. Goldberger et al⁹ observed an association of effects on cIMT progression and risk of myocardial

infarction, whereas Costanzo et al¹⁰ found no statistically significant association of changes in mean or maximal cIMT with risk of myocardial infarction or stroke. Both meta-analyses have been criticized because of methodological flaws.¹¹

To address this uncertainty, we conducted a comprehensive analysis of 119 RCTs involving a total of 100 667 patients. Our aims were to: (1) quantify the reduction in CVD risk associated with reducing cIMT progression by therapeutic intervention; (2) explore cIMT progression as a surrogate marker for different types of CVD end points as well as all-cause mortality; and (3) investigate differences according to the intervention type, method of cIMT assessment, and other trial characteristics.

METHODS

The datasets supporting the conclusions of this article are not made publicly available because of legal restrictions arising from the data distribution policy of the PROG-IMT (Individual Progression of Carotid Intima Media Thickness as a Surrogate for Vascular Risk)/Proof-ATHERO (Prospective Studies of Atherosclerosis) collaborations and from the bilateral agreements between the consortium's coordinating center and participating studies, but they may be requested directly from individual study investigators. Studies that shared individual-participant data have obtained informed consent of the study participants and ethical approval by their respective institutional review boards.

The report of the results of our study adhere to the PRISMA-IPD (Preferred Reporting Items for Systematic Reviews and Meta-Analyses—Individual Patient Data) guidelines (Table 1 in the Data Supplement); the objectives and statistical methods in this paper have been described previously.¹² We identified relevant RCTs published before February 3, 2020, through systematic searches of 10 medical knowledge databases, 6 clinical trial registries, and reference lists of relevant publications and reviews (Table 2 in the Data Supplement). Trials were eligible for inclusion if they: (1) had assigned patients randomly to 2 or more arms; (2) had applied well-defined inclusion criteria; (3) had measured cIMT at trial baseline and at ≥ 1 follow-up visits; and (4) had recorded incident CVD outcomes. We requested anonymized patient-level data from these trials, performed comprehensive plausibility checks, and were able to resolve any data-related queries through direct correspondence with trial investigators. For trials for which patient-level data were unavailable, 4 authors (PW, LT, EA, MWL) independently extracted the relevant data from the published literature and resolved any discrepancies by consensus.

As a measure of cIMT, we gave preference to assessments of mean values at the common-carotid-artery. If unavailable, we used maximum values at the common-carotid-artery or cIMT at other sections of the carotid artery instead. In trials quantifying cIMT values at different sites (ie, left or right side, near or far vessel wall, or at different insonation angles), the arithmetic mean of these measurements was used. The primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures (eg, coronary or carotid revascularization), or fatal CVD. For trials without data on cause-specific death, all-cause mortality

was included in the primary outcome instead. [Table III in the Data Supplement](#) provides details on the assessment of cIMT progression and primary outcome definition in each trial.

Statistical Analysis

We conducted analyses according to a prespecified analysis plan. For factorial trials, we analyzed the intervention contrast anticipated to have the greatest effect on CVD risk. For trials with more than 2 trial arms, we compared the arm that was, based on previous trials, anticipated to have the greatest effect to the arm anticipated to have the least effect (or no effect in case of placebo). For all trials, the latter group was used as reference.

The principal analysis consisted of 3 steps. First, we quantified intervention effects on cIMT progression. For each trial for which patient-level data were available, we used a linear mixed model to estimate the difference in yearly cIMT progression between trial arms. The model included fixed effects for assigned treatment, time in study, and the interaction of the 2, plus an intercept and time variable allowed to vary randomly at the patient level. For each trial for which literature-based data were available (ie, tabular data extracted from the trials' publications), we annualized differences in cIMT progression and calculated standard errors from *P* values, if necessary.

Second, we quantified intervention effects on the CVD outcome. For each trial with patient-level data, we fitted a Cox proportional-hazards model to estimate the log hazard ratio and its standard error comparing the trial arms. If estimates were inestimable because of a low event number, we applied an augmentation procedure to allow incorporation of the trial in the meta-analysis.¹³ For each trial with literature-based data, we calculated the log risk ratio and its standard error on the basis of the number of events and patients in each trial arm. For trials in which 1 arm had zero events, the number of events and nonevents were each augmented by +0.5 in both trial arms. Hazard ratios and risk ratios are collectively described as measures of relative risk (RR).

Third, to test whether effects on CVD risk depended on effects on cIMT progression, we used a Bayesian meta-regression approach that models both effects simultaneously, while taking into account the estimated precisions in these 2 effects.¹⁴ The principal analysis involved: (1) a model with an intercept of zero (ie, forcing the regression line through the origin and thereby assuming that all the effects on CVD risk operate through cIMT progression), and (2) a model with a nonzero intercept (ie, allowing for an effect on CVD risk independent of cIMT progression). The meta-regression also took into account the within-study correlation of the 2 effects, which was estimated using bootstrapping in the trials with patient-level data and >30 events.¹⁵ For other trials, an overall correlation coefficient pooled using random-effects meta-analysis was used instead. Further details on methods for assessing surrogacy are provided in the [Methods in the Data Supplement](#).

Subsidiary analyses evaluated surrogacy for individual disease end points and in trials grouped by intervention type, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measure, and proportion of female

patients. A Bayesian approach was taken for estimation of the meta-regression model parameters and for prediction (for details, see the [Methods in the Data Supplement](#)). Analyses were performed using Stata 15, R 2.5.1, and JAGS 4.3.0. PW had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

RESULTS

Among 10 260 articles screened, we identified 119 trials involving 100 667 patients that met the prespecified inclusion criteria ([Figure I in the Data Supplement](#)). 103 trials (87%) had 2 arms, 7 had 3 arms, 1 had 4 arms, 7 had a 2x2 factorial design, and 1 had a 3x2 factorial design (Table). The trials used antidiabetic (18 trials), antihypertensive (19 trials), dietary/vitamin (20 trials), lipid-lowering (33 trials), or other interventions (37 trials). Mean age at baseline was 62 years (standard deviation 8); 42% were female. Over an average follow-up duration of 3.7 years, 12 038 patients developed the primary CVD end point. The median proportion of patients with repeat cIMT measurements across trials was 90%. Seven large cardiovascular outcome trials had measured cIMT only in a subset of patients (Table). Mean cIMT measured at the common-carotid-artery was available in 91 trials, maximum cIMT at the common-carotid-artery in 49 trials, and other cIMT measures in 11 trials. Across contributing trials, the mean rate of cIMT progression was +9.1 $\mu\text{m}/\text{y}$ (95% confidence interval, 7.1–11.1) in control arms and +1.0 $\mu\text{m}/\text{y}$ (–0.6 to 2.7) in interventions arms. Across all contributing trials, the RR for CVD with intervention was 0.88 (0.83–0.92).

Results of the principal analysis are provided in Figure 1. Across all interventions, in the model assuming an intercept of zero, each 10 μm per year reduction of cIMT progression was associated with a RR for CVD of 0.88 (95% credible interval [CrI], 0.85–0.91). In the model allowing for a nonzero intercept, the RR for CVD was 0.91 (0.87–0.94) per 10 $\mu\text{m}/\text{y}$ slower cIMT progression, with a further RR of 0.92 (0.87–0.97) achieved independent of cIMT progression. Using the nonzero intercept model, the proportion of variance in the CVD outcome explained by cIMT progression was 98% albeit with a wide 95% CrI (71% to 100%). Taken together, we estimated that interventions that reduce cIMT progression by 10, 20, 30, or 40 $\mu\text{m}/\text{y}$ would yield RRs of 0.84 (0.75–0.93), 0.76 (0.67–0.85), 0.69 (0.59–0.79), or 0.63 (0.52–0.74), respectively.

Owing to presence of effects on CVD risk unexplained by cIMT progression, subsequent analyses focused on the nonzero intercept model. In outcome-specific analyses (Figure 2), RRs per 10 $\mu\text{m}/\text{y}$ slower cIMT progression were 0.88 (0.82–0.94) for myocardial infarction, 0.92 (0.86–1.00) for stroke, 0.90 (0.83–0.98) for revascularization procedures, 0.91 (0.83–1.01) for




Figure 1. Intervention effects on carotid intima-media thickness progression plotted against intervention effects on risk for the primary cardiovascular disease end point.

The intercept of the primary model was 0.92 (95% CI, 0.87–0.97). Each bubble represents a trial. Trials with point estimates outside of this area are indicated with the symbol x. The areas of the bubbles are proportional to the inverse variance of the log relative risk for the primary cardiovascular disease (CVD) end point. The shaded areas around lines of fit are 95% prediction intervals. For purpose of presentation, the graph area was limited to –80 to 80 $\mu\text{m}/\text{y}$ on the horizontal axis and 0.25 to 4 on the vertical axis. CI indicates credible interval; cIMT, carotid intima-media thickness; and RR, relative risk.

fatal CVD, and 0.96 (0.89–1.04) for all-cause mortality. There was no evidence for differences in the RR for CVD associated with slower cIMT progression nor in the intercept across trials grouped by intervention type (Figure 3 and Figure 4). There was also no evidence for differences in these RRs in trials grouped by time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurements, or proportion of female patients (Figure 4, *P* values for heterogeneity >0.05). In a sensitivity analysis that omitted trials with extreme effect sizes (ie, cIMT progression changes $>80 \mu\text{m}/\text{y}$ or RR for CVD <0.25 or >4.0), the RR for CVD per $10 \mu\text{m}/\text{y}$ slower cIMT progression was 0.91 (0.87–0.95). Results were also highly robust across leave-one-out cross-validation analyses (Figure II in the Data Supplement). Trial-specific estimates are provided in Table IV in the Data Supplement.

DISCUSSION

In this large-scale meta-analysis involving data from 119 RCTs and 100 667 patients, we showed that interventions reducing cIMT progression are also likely to reduce CVD event rates (summarized in Figure 5). To be specific, a $10 \mu\text{m}/\text{y}$ slower cIMT progression was associated with a RR of 0.91 (95% CI, 0.87–0.94) for the principal outcome of CVD, with the differences in RR for CVD largely explained by the differences in cIMT progression. The same model also indicated a nonzero intercept, overall and for different types of interventions, highlighting that a small but significant proportion of the intervention effect acted independently of cIMT progression. By estimating CVD risk reductions according to specific reductions in cIMT progression, we provide guidance to future trials in the cardiovascular field.⁵ Results were robust for a range




Figure 2. Intervention effects on risk for individual cardiovascular disease end points and all-cause mortality per 10 $\mu\text{m}/\text{y}$ slower carotid intima-media thickness progression.

*The relative risks (RRs) for intercepts are the effects achieved independent of carotid intima-media thickness (cIMT) progression. CI indicates credible interval; and CVD, cardiovascular disease.

of disease end points and across clinically important trial characteristics, including type of intervention or type of cIMT measurement.

Exploring the association between cIMT and CVD risk has some history. cIMT measured at a single time-point is associated with incident CVD and provides




Figure 3. Intervention effects on carotid intima-media thickness progression plotted against intervention effects on risk for the primary cardiovascular disease end point, according to type of intervention.

The RRs for intercepts as well as *P* values for heterogeneity of intercept and slope are provided in Figure 4. The areas of the bubbles are proportional to the inverse variance of the log relative risk for the primary cardiovascular disease (CVD) end point. For purpose of presentation, the graph area was limited to -80 to 80 $\mu\text{m}/\text{y}$ on the horizontal axis and 0.25 to 4 on the vertical axis. Trials with point estimates outside of this area are indicated with the symbol *x*. cIMT indicates, carotid intima-media thickness; and RR, relative risk.




Figure 4. Intervention effects on risk for the primary cardiovascular disease end point per 10 $\mu\text{m}/\text{y}$ slower carotid intima-media thickness progression, according to trial characteristics.

*P values for heterogeneity. §The relative risks (RRs) for intercepts are the effects achieved independent of carotid intima-media thickness (cIMT) progression.

||Numbers of trials across some subgroups do not sum to 119 because of missing information or contribution of trials to multiple subgroups. CCA-IMT indicates intima-media thickness of the common-carotid-artery; CI, credible interval; and IPD, individual-participant data.

incremental predictive value over and beyond conventional CVD risk factors.^{190–192} For cIMT progression over time, our earlier analyses of observational studies within the PROG-IMT collaboration indicated no statistically significant association with subsequent CVD risk in individuals of the general population,² patients with diabetes mellitus,¹⁹³ or patients at high CVD risk.¹⁹⁴ This null association could be explained by the challenges of precisely estimating cIMT progression in individuals over time. In contrast, our present report focuses on groups of patients in RCTs and is therefore better suited to provide answers about the surrogate value of cIMT progression. Averaging across patients improves the signal-to-noise ratio, confounders are expected to be balanced because of randomization, trial cohorts might be more homogeneous, and cIMT protocols may be of higher quality in clinical trial settings.

Previous RCT data on cIMT progression as a surrogate marker for CVD risk are limited. Because most RCTs

reporting both cIMT and end points (with few exceptions)^{63,70,97,127,170} have not been designed as CVD outcome trials and because a range of intervention effect sizes is needed for meaningful results, meta-analysis is the method of choice to investigate this question.¹⁹⁵ Three such pooled analyses had been undertaken before. Espeland et al demonstrated that statin treatment reduced cIMT progression and CVD risk in a concordant manner.⁴ In a meta-analysis involving 28 RCTs of different intervention types, Goldberger et al observed an association between reduced cIMT progression and lower risk for nonfatal myocardial infarction, but noted marked between-trials heterogeneity.⁹ A meta-analysis by Costanzo et al, involving 41 RCTs, demonstrated no statistically significant relationship between slower cIMT progression and risk of cardiovascular outcomes.¹⁰ Compared with these earlier reports, our meta-analysis stands out by: (1) exclusively conducting within-trial comparison (thereby upholding the principle of




Figure 5. Summary of key findings of our study.

CI indicates credible interval; cIMT, carotid intima-media thickness; CVD, cardiovascular disease; and RCTs, randomized, controlled trials.

randomization); (2) increasing statistical power by involving >5 times as many patients as the previously largest report;¹⁰ (3) enhancing validity by accessing patient-level data of 28 trials; and (4) using modern statistical methods that incorporate uncertainties both around the intervention effects on cIMT progression and CVD risk as well as their within-trial correlation.

What do we know about the suitability of cIMT progression as a surrogate marker for CVD risk? Ultrasound-based cIMT measurement fulfills several requirements of a surrogate marker,¹⁹⁶ including: (1) high correlation with thickness of the vessel wall measured in histological samples;¹⁹⁷ (2) acceptable reproducibility,¹⁹⁸ which was further enhanced by clear recommendations for measurement and technical improvements¹⁹⁹; (3) close correlation with risk factors and prevalent CVD;^{190–192} (4) established correlation with atherosclerosis in other vascular beds;¹⁹⁶ (5) association with occurrence of clinical events;^{190–192} (6) the ability to change over time;^{2,193} and (7) the possibility to influence cIMT with interventions.²⁰⁰ In the present analysis, we have provided evidence for the last missing requirement not credibly proven by earlier studies, namely that a change in cIMT progression is related to the change in risk of CVD events.

It is important that using cIMT progression as a surrogate end point in future RCTs may facilitate and speed up development and licensing of new therapies. To illustrate this point, we conducted a sample size calculation for a hypothetical future trial. For this calculation, we assumed 80% power, several parameters similar to our individual-participant data (ie, 2-year cumulative incidence of CVD 6.57%, a standard deviation of cIMT 178 µm, and a correlation between baseline and follow-up cIMT 0.79), no losses to follow-up, and a perfect relationship between treatment effects on cIMT progression and those on the CVD outcome. To have 80% power to detect a hazard ratio of 0.84, a future 2-year CVD outcome trial would require 8600 patients in each trial arm. In comparison, a future 2-year cIMT progression trial would require 470 patients per trial arm to detect a 10 µm/y reduction in cIMT progression (corresponding to the above hazard ratio) at 2-years, also with a power of 80%. Consequently, a cIMT trial would only require 5.5% of the sample size of a comparable CVD end point trial.

In addition to demonstrating the association between intervention effects on cIMT and intervention effects on CVD risk, we found that the regression line had a small but significant nonzero intercept, in the overall analysis and in

Table 1. Key Features of the Trials Included in This Report

Trial	Years of Baseline	Country	Access to IPD	No. of Trial Arms	Type of Intervention*				
					Anti-Diabetic	Anti-Hypertensive	Dietary / Vitamins	Lipid-Lowering	Other
ACAPS ^{16,17}	1989–1990	USA	●	2x2	-	-	-	●	●
ACT NOW ^{18,19}	2004–2006	USA	-	2	●	-	-	-	-
ALLO-IMT ²⁰	2009–2010	UK	●	2	-	-	-	-	●
AMAR ²¹	2004–2005	Russia	-	2	-	-	●	-	-
ARBITER ²²	1999–2001	USA	-	2	-	-	-	●	-
ARBITER 2 ²³	2001–2003	USA	-	2	-	-	-	●	-
ARBITER 6-HALTS ^{6,24,25}	2006–2009	USA	-	2	-	-	-	●	-
ARTSTIFF ²⁶	2008–2011	International	-	3	-	●	-	-	-
ASAP-FINLAND ^{27–29}	1994–1995	Finland	-	2	-	-	●	-	-
ASAP-NL ^{30,31}	1997–1998	Netherlands	-	2	-	-	-	●	-
ASFAST ³²	1998–2000	International	-	2	-	-	●	-	-
ATIC ^{33,34}	2001–2002	Netherlands	-	2	-	-	-	-	●
Ahn et al ³⁵	2005–2006	Korea	-	2	-	-	-	-	●
Andrews et al ^{36,37}	2011–2015	USA	-	2	-	-	-	-	●
BCAPS ³⁸	1994–1996	Sweden	-	2x2	-	●	-	●	-
BKREGISTRY-II ³⁹	2000–2003	Korea	●	2	-	-	-	●	-
BVAIT ⁴⁰	2000–2006	USA	-	2	-	-	●	-	-
CAIUS ⁴¹	1991–1992	Italy	-	2	-	-	-	●	-
CAMERA ⁴²	2009–2011	UK	●	2	●	-	-	-	-
CAPPA ⁴³	2009	Korea	-	2	-	-	-	-	●
CAPTIVATE ⁴⁴	2004–2005	International	-	2	-	-	-	●	-
CERDIA ⁴⁵	1999–2001	Netherlands	●	2	-	-	-	●	-
CHICAGO ⁴⁶	2003–2005	USA	-	2	●	-	-	-	-
CIMT phase 1 ^{47,48}	2008–2009	Denmark	-	2	●	-	-	-	-
CLAS ^{49–51}	1980–1984	USA	-	2	-	-	-	●	-
CONTRAST ^{52,53}	2004–2009	Netherlands	●	2	-	-	-	-	●
Cao et al ⁵⁴	2008–2011	China	-	2	-	-	●	-	-
DAPC ^{55,56}	2004–2006	International	-	2	-	-	-	-	●
DAPHNE ⁵⁷	NR	Netherlands	-	2	-	●	-	-	-
DOIT ⁵⁸	1997–1999	Norway	-	2	-	-	●	-	-
EGE STUDY ^{59,60}	2005–2006	Turkey	●	2x2	-	-	-	-	●
ELITE (early MP) ^{61,62}	2005–2008	USA	-	2	-	-	-	-	●
ELITE (late MP) ^{61,62}	2005–2008	USA	-	2	-	-	-	-	●
ELSA ⁶³	NR	International	-	2	-	●	-	-	-
ELVA ⁶⁴	NR	Sweden	-	2	-	●	-	-	-
ENCORE ^{65,66}	2003–2008	USA	●	3	-	-	●	-	-
ENHANCE ⁶⁷	2002–2004	International	●	2	-	-	-	●	-
EPAT ⁶⁸	1994–1998	USA	-	2	-	-	-	-	●
FIELD ^{69,70}	1998–2000	International	-	2	-	-	-	●	-
FIRST ^{71,72}	2008–2010	USA	-	2	-	-	-	●	-
FRANCIS ^{73,74}	2011–2012	Netherlands	-	2	-	-	-	-	●
GRACE ⁷⁵	2003–2005	International	●	2x2	●	-	●	-	-

(Continued)

Table 1. Continued

No. of Patients	Type of Population	Mean Age (SD), yrs	% Female	CVD Risk		cIMT Progression				
				Median Follow-Up, yrs	No. of Events	Maximum Follow-Up, yrs	% With cIMT data	Mean CCA-IMT	Max CCA-IMT	Other cIMT
919	Elevated CVD risk	62 (8)	48	5.0	18	6.0	100	-	●	-
602	Dysglycemia	52 (10)	58	2.2†	13	4.0	63	●	-	-
80	Preexisting CVD	68 (10)	43	1.0	11	1.2	100	●	●	-
257	Elevated CVD risk	61 (9)	0	2.0‡	21	2.0	76	●	-	-
161	Elevated CVD risk	60 (12)	29	1.0‡	6	1.0	86	●	●	-
167	Preexisting CVD	67 (10)	9	1.0‡	10	1.0	89	●	-	-
363	Preexisting CVD	65 (10)	20	1.2‡	11	1.2	57	●	●	-
133	Hypertension	53 (10)	37	1.0‡	0	1.0	87	●	-	-
520	Hyperlipidemia	60 (6)	51	6.0‡	22	6.0	85	●	-	-
330	Hyperlipidemia	49 (11)	61	2.0‡	5	2.0	85	●	-	-
315	Kidney disease	56 (13)	32	3.3†	73	3.6	77	-	●	-
93	Kidney disease	53 (12)	43	2.0‡	4	1.5	80	●	-	-
130	Preexisting CVD	64 (11)	38	2.0‡	18	2.0	73	-	-	●
80	Kidney disease	57 (12)	20	0.2‡	1	0.2	79	●	-	-
793	Elevated CVD risk	62 (5)	54	3.0†	18	3.0	99	●	-	-
205	Preexisting CVD	60 (10)	32	0.5	3	1.1	59	●	-	-
506	General population	61 (10)	39	3.1†	20	2.5	97	●	-	-
305	Hyperlipidemia	55 (6)	47	3.0‡	5	3.0	100	-	●	-
173	Preexisting CVD	63 (8)	23	1.5	12	2.3	100	●	-	-
420	Dysglycemia	60 (9)	50	3.0‡	6	3.0	99	●	●	-
892	Hyperlipidemia	55 (9)	39	2.0‡	32	1.0	99	-	-	●
250	Dysglycemia	58 (11)	53	2.1	14	2.5	99	●	●	-
462	Dysglycemia	60 (8)	37	1.4‡	13	1.4	78	●	●	-
412	Dysglycemia	61 (9)	32	1.5‡	20	1.5	100	●	●	-
162	Preexisting CVD	54 (5)	0	7.0†	82	4.0	48	●	-	-
714	Kidney disease	64 (14)	38	2.4	173	3.1	20	●	●	-
287	Elevated CVD risk	71 (13)	53	2.0‡	36	2.0	100	-	-	●
329	Dysglycemia	64 (7)	48	2.0‡	3	2.0	90	●	●	-
80	Preexisting CVD	59 (7)	0	3.0‡	16	3.0	100	-	-	●
561	Elevated CVD risk	70 (5)	0	3.0‡	63	3.0	83	●	-	-
644	Kidney disease	59 (14)	46	3.0	60	3.0	100	●	-	-
271	General population	55 (4)	100	5.0	1	5.0	92	●	-	-
372	General population	65 (6)	100	5.0	5	5.0	94	●	-	-
2334	Hypertension	56 (7)	45	4.0‡	60	4.0	87	-	-	●
129	Hyperlipidemia	60 (10)	49	3.0‡	4	3.0	71	●	-	-
144	Elevated CVD risk	52 (10)	67	0.4	1	1.1	98	●	-	-
720	Hyperlipidemia	47 (9)	49	2.0	52	2.3	100	●	●	-
222	Hyperlipidemia	61 (7)	100	2.0‡	7	2.0	90	●	-	-
9795	Dysglycemia	62 (7)	37	6.0‡	1295	5.0	2	-	●	-
682	Preexisting CVD	61 (9)	32	2.1‡	30	2.0	84	-	●	-
320	Elevated CVD risk	53 (11)	70	5.0‡	9	5.0	100	●	-	-
1189	Dysglycemia	63 (8)	36	5.8	374	5.1	100	●	●	-

(Continued)

Table 1. Continued

Trial	Years of Baseline	Country	Access to IPD	No. of Trial Arms	Type of Intervention*				
					Anti-Diabetic	Anti-Hypertensive	Dietary / Vitamins	Lipid-Lowering	Other
Gresele et al ⁷⁶	2003–2005	International	●	2	-	-	-	-	●
HART ⁷⁷	1999–2000	International	●	2	-	-	●	-	-
HERS ^{78,79}	1993–1994	USA	-	2	-	-	-	-	●
HYRIM ⁸⁰	1997–1999	Norway	●	2x2	-	-	-	●	●
INSIGHT ^{81–83}	1994–1996	France	-	2	-	●	-	-	-
J-STARS ^{84–88}	2004–2009	Japan	-	2	-	-	-	●	-
JART ⁸⁹	2008–2010	Japan	-	2	-	-	-	●	-
KAPS ⁹⁰	1984–1989	Finland	-	2	-	-	-	●	-
KEEPS ⁹¹	2005–2008	USA	-	3	-	-	-	-	●
KIMVASC ⁹²	2011–2012	UK	●	2	-	-	●	-	-
Katakami et al ⁹³	1998	Japan	-	3	●	-	-	-	-
Koyasu et al ⁹⁴	2006–2008	Japan	-	2	●	-	-	-	-
LAARS ⁹⁵	NR	International	-	2	-	●	-	-	-
LIFE-ICARUS ⁹⁶	1996–1997	International	●	2	-	●	-	-	-
LIPID ^{97–100}	1990–1992	International	-	2	-	-	-	●	-
Luijendijk et al ^{101,102}	2007–2009	Netherlands	-	2	-	-	-	●	-
MARS ^{103,104}	1985–1989	USA	-	2	-	-	-	●	-
MAVET ¹⁰⁵	1994–1995	Australia	-	2	-	-	●	-	-
MECANO ^{106,107}	2005–2006	Netherlands	-	2	-	-	-	-	●
MEDICLAS ^{108,109}	2003–2005	Netherlands	●	2	-	-	-	-	●
METEOR ¹¹⁰	2002–2004	International	-	2	-	-	-	●	-
MG600 ¹¹¹	2010–2011	Brazil	●	2	-	-	●	-	-
MIDAS ¹¹²	NR	USA	-	2	-	●	-	-	-
MITEC ^{113,114}	2000–2002	France	-	2	-	●	-	-	-
Makimura et al ¹¹⁵	2008–2010	USA	-	2	-	-	-	-	●
Masia et al ¹¹⁶	2006–2007	Spain	●	2	-	-	-	-	●
Mitsuhashi et al ¹¹⁷	NR	Japan	-	2	-	-	-	-	●
Mortazavi et al ¹¹⁸	NR	Iran	-	2	-	-	●	-	-
NTPP ¹¹⁹	2005–2010	Japan	-	2	-	-	-	●	-
Nakamura et al II ¹²⁰	2001	Japan	●	2	-	-	-	-	●
Ntaios et al ¹²¹	2005	Greece	●	2	-	-	●	-	-
OPAL ^{122,123}	1997–1999	International	●	3	-	-	-	-	●
PART-2 ¹²⁴	NR	New Zealand	-	2	-	●	-	-	-
PEACE ¹²⁵	2007–2008	Japan	-	2	-	-	-	●	-
PERFORM ^{126,127}	2006–2008	International	-	2	-	-	-	-	●
PERIOCARDIO ¹²⁸	2010–2012	Australia	●	2	-	-	-	-	●
PHOREA ¹²⁹	1995–1996	Germany	-	3	-	-	-	-	●
PHYLLIS ^{130,131}	1995–1997	Italy	-	4	-	●	-	●	-
PLAC II ^{132–134}	1987–1990	USA	-	2	-	-	-	●	-
PPAR ¹³⁵	2002–2003	International	-	2	●	-	-	-	-
PREDIMED ^{136,137}	2008–2009	Spain	-	3	-	-	●	-	-

(Continued)

Table 1. Continued

No. of Patients	Type of Population	Mean Age (SD), yrs	% Female	CVD Risk		cIMT Progression				
				Median Follow-Up, yrs	No. of Events	Maximum Follow-Up, yrs	% With cIMT data	Mean CCA-IMT	Max CCA-IMT	Other cIMT
442	Preexisting CVD	67 (9)	21	0.6	8	0.6	57	●	●	-
925	Preexisting CVD	69 (7)	24	5.0	152	5.6	100	●	●	-
2763	General population	67 (7)	100	4.1†	552	4.7	16	-	●	-
568	Hypertension	57 (9)	0	4.1	47	4.6	99	-	●	-
6321	Elevated CVD risk	65 (7)	54	3.5†	347	4.0	5	●	-	-
1589	Preexisting CVD	66 (8)	31	4.9†	290	5.0	50	●	-	-
348	Hyperlipidemia	64 (9)	51	2.0‡	9	2.0	40	●	●	-
447	Hyperlipidemia	57 (4)	0	3.0‡	28	3.0	95	-	●	-
727	General population	53 (3)	100	4.0‡	1	4.0	100	●	-	-
80	Preexisting CVD	77 (5)	45	0.5	1	0.5	99	●	-	-
159	Dysglycemia	61 (9)	51	3.3†	0	3.3	74	-	-	●
90	Preexisting CVD	66 (8)	9	1.0‡	0	1.0	90	-	●	-
280	Hypertension	59 (9)	50	2.0‡	0	2.0	72	●	-	-
83	Hypertension	67 (6)	27	4.9	8	3.1	98	●	-	-
9014	Preexisting CVD	61 (8)	17	6.1†	3229	4.0	4	●	-	-
155	Preexisting CVD	36 (12)	38	3.3†	0	4.4	100	●	-	-
270	Hyperlipidemia	58 (7)	9	2.2†	54	4.0	27	●	-	-
409	Elevated CVD risk	64 (6)	55	4.0‡	6	4.0	81	-	●	-
185	Kidney disease	51 (13)	36	1.5‡	6	2.0	88	●	-	-
48	Elevated CVD risk	42 (10)	0	3.0	1	3.2	77	●	-	-
984	Elevated CVD risk	57 (6)	40	2.0‡	3	2.0	89	●	●	-
35	Hypertension	55 (7)	100	0.5	0	0.5	100	●	●	-
883	Hypertension	59 (9)	22	3.0‡	47	3.0	100	-	●	-
209	Elevated CVD risk	60 (8)	36	3.0‡	0	3.0	41	●	-	-
60	Elevated CVD risk	41 (2)	35	1.0‡	0	1.0	97	●	-	-
68	Elevated CVD risk	52 (11)	10	6.0	4	6.9	99	●	●	-
62	Dysglycemia	63 (7)	35	2.6†	1	2.6	100	-	-	●
54	Kidney disease	57 (12)	50	0.5‡	1	0.5	96	●	-	-
123	Elevated CVD risk	59 (9)	54	3.0‡	0	3.0	79	●	●	-
50	Kidney disease	53 (7)	40	6.9	8	4.1	100	●	●	-
103	Elevated CVD risk	73 (5)	45	1.5	18	1.5	100	●	-	-
866	General population	59 (7)	100	3.1	9	3.7	100	●	●	-
617	Preexisting CVD	61 (8)	18	4.7†	150	4.0	87	●	-	-
303	Hyperlipidemia	66 (9)	43	1.0‡	2	1.0	74	●	●	-
19 120	Preexisting CVD	67 (8)	37	2.4†	2910	3.0	5	●	-	-
273	Elevated CVD risk	41 (10)	42	1.0	3	1.4	99	●	●	-
321	General population	59 (4)	100	0.9‡	1	0.9	54	-	●	-
508	Elevated CVD risk	58 (7)	60	2.6†	6	2.6	82	-	●	-
151	Elevated CVD risk	63 (NR)	15	3.0‡	14	3.0	100	-	●	-
200	Elevated CVD risk	59 (10)	20	1.0‡	17	1.0	100	-	-	●
7447	Elevated CVD risk	67 (6)	57	4.8	288	2.4	2	●	●	-

(Continued)

Table 1. Continued

Trial	Years of Baseline	Country	Access to IPD	No. of Trial Arms	Type of Intervention*				
					Anti-Diabetic	Anti-Hypertensive	Dietary / Vitamins	Lipid-Lowering	Other
PREVEND IT ¹³⁸⁻¹⁴¹	1998–1999	Netherlands	●	2x2	-	●	-	●	-
PREVENT ^{142,143}	1992–1997	International	-	2	-	●	-	-	-
PROBE ^{144,145}	2002–2003	Japan	-	2	●	-	-	-	-
RADIANCE I ^{146,147}	2003–2004	International	●	2	-	-	-	●	-
RADIANCE II ^{147,148}	2004–2006	International	●	2	-	-	-	●	-
RAS ¹⁴⁹	2002–2003	Sweden	-	2	●	-	-	-	-
REGRESS ^{150,151}	1989–1991	Netherlands	-	2	-	-	-	●	-
REMOVAL ^{152,153}	2011–2014	International	-	2	●	-	-	-	-
RIS ¹⁵⁴	1987–1989	Sweden	●	2	-	-	-	-	●
SANDS ¹⁵⁵⁻¹⁵⁷	2003–2004	USA	-	2	-	-	-	-	●
SCIMO ^{158,159}	1992–1994	Germany	-	2	-	-	●	-	-
SECURE ¹⁶⁰	1994–1995	Canada	●	3x2	-	●	●	-	-
SEKONA ¹⁶¹	2004–2005	Germany	-	2	-	-	-	-	●
SENDCAP ¹⁶²	1990–1993	UK	-	2	-	-	-	●	-
SPEAD-A ^{163,164}	2011–2013	Japan	-	2	●	-	-	-	-
SPIKE ¹⁶⁵⁻¹⁶⁷	2012	Japan	-	2	●	-	-	-	-
STARR ¹⁶⁸	2001–2003	International	●	2x2	●	●	-	-	-
STOP-NIDDM ^{169,170}	1996–1998	Germany	-	2	●	-	-	-	-
Safarova et al ¹⁷¹	2007–2009	Russia	●	2	-	-	-	●	-
Sander et al (Cp neg) ^{172,173}	1995–1998	Germany	-	2	-	-	-	-	●
Sander et al (Cp pos) ^{172,173}	1995–1998	Germany	-	2	-	-	-	-	●
Spring et al ¹⁷⁴	NR	Switzerland	-	2	-	-	-	●	-
Stanley et al ¹⁷⁵	2011–2013	USA	-	2	-	-	-	-	●
Stanton et al ¹⁷⁶	NR	UK	-	2	-	●	-	-	-
TART ¹⁷⁷	1997–1998	USA	-	2	●	-	-	-	-
TEAAM ¹⁷⁸	2004–2009	USA	-	2	-	-	-	-	●
TRIPOD ¹⁷⁹	1995–1998	USA	-	2	●	-	-	-	-
Tasic et al ¹⁸⁰	NR	Serbia	-	2	-	●	-	-	-
VEAPS ¹⁸¹	1996–1999	USA	-	2	-	-	●	-	-
VHAS ^{182,183}	NR	Italy	-	2	-	●	-	-	-
VIP ¹⁸⁴	2005–2007	Netherlands	-	2	-	-	-	-	●
VITAL ¹⁸⁵	2002–2004	Netherlands	●	2	-	-	-	-	●
WISH ¹⁸⁶	2004–2007	USA	-	2	-	-	●	-	-
Yang et al ¹⁸⁷	2013–2017	China	-	2	-	-	-	-	●
Yun et al ¹⁸⁸	2010–2013	China	-	2	●	-	-	-	-
Zou et al ¹⁸⁹	2010	China	-	2	-	-	●	-	-
Total: 119 trials	1980–2017		30		18	19	20	33	37

(Continued)

Table 1. Continued

No. of Patients	Type of Population	Mean Age (SD), yrs	% Female	CVD Risk		cIMT Progression				
				Median Follow-Up, yrs	No. of Events	Maximum Follow-Up, yrs	% With cIMT data	Mean CCA-IMT	Max CCA-IMT	Other cIMT
864	Kidney disease	51 (12)	35	3.9	102	4.7	94	●	-	-
825	Elevated CVD risk	57 (10)	20	3.0†	196	3.0	46	-	●	●
587	Dysglycemia	58 (NR)	37	4.0†	14	3.3	30	●	●	-
904	Hyperlipidemia	46 (13)	51	2.0	44	2.3	98	●	●	-
752	Hyperlipidemia	57 (8)	36	2.0	37	2.4	98	●	●	-
557	Elevated CVD risk	67 (6)	54	1.0†	5	1.0	80	●	-	-
885	Elevated CVD risk	56 (8)	0	2.0†	148	2.0	29	●	-	-
428	Dysglycemia	56 (9)	41	3.0†	17	3.0	99	●	●	-
164	Elevated CVD risk	66 (5)	0	5.9	47	7.3	99	●	●	-
499	Elevated CVD risk	56 (9)	66	3.0†	18	3.0	100	●	-	-
223	Elevated CVD risk	58 (9)	20	2.0†	55	2.0	77	-	●	-
731	Elevated CVD risk	66 (7)	24	4.4	103	5.3	100	-	●	-
600	Elevated CVD risk	49 (6)	11	3.0†	110	3.0	66	●	-	-
164	Dysglycemia	51 (8)	29	3.0†	4	3.0	77	-	●	-
341	Dysglycemia	65 (9)	42	2.0†	4	2.0	94	●	●	-
282	Dysglycemia	64 (7)	40	2.0†	6	2.0	97	●	●	-
1320	Dysglycemia	53 (11)	55	4.2	30	4.5	100	●	●	-
1429	Dysglycemia	55 (8)	51	3.3†	47	3.9	8	●	-	-
60	Preexisting CVD	55 (6)	0	3.0	40	2.8	100	●	-	-
147	Preexisting CVD	64 (12)	44	3.0†	9	2.0	100	●	-	-
125	Preexisting CVD	65 (14)	43	3.0†	19	2.0	100	●	-	-
100	Preexisting CVD	67 (11)	22	0.5†	2	0.5	89	●	-	-
50	Elevated CVD risk	51 (7)	16	0.5†	1	0.5	86	●	-	-
69	Hypertension	48 (11)	41	1.0†	1	1.0	80	●	-	-
299	Dysglycemia	52 (9)	66	2.0	12	2.0	92	●	-	-
308	General population	68 (5)	0	3.0†	16	3.0	99	●	-	-
266	Dysglycemia	34 (7)	100	2.9	0	4.0	72	●	-	-
40	Hypertension	64 (9)	35	0.8†	6	0.8	100	●	-	-
353	Hyperlipidemia	56 (9)	52	3.0†	18	3.0	94	●	-	-
1414	Hypertension	54 (7)	51	2.0†	33	4.0	27	-	-	●
119	Kidney disease	53 (12)	33	3.0†	10	3.0	86	●	-	-
199	Elevated CVD risk	49 (12)	41	1.5	12	2.5	99	●	-	-
350	General population	61 (7)	100	2.7	1	3.0	93	●	-	-
119	Elevated CVD risk	54 (11)	72	0.5†	0	0.5	100	-	-	●
135	Preexisting CVD	62 (5)	40	2.3†	23	4.5	93	●	-	-
96	Elevated CVD risk	57 (5)	59	1.0†	0	1.0	89	●	-	-
100667		62 (8)	41.9	3.7	12038	3.5	90	91	49	11

Table V in the Data Supplement provides full names of the contributing trials. *Table III in the Data Supplement provides detailed information on the interventions in each trial. †Mean. ‡Maximum. CCA-IMT indicates common-carotid-artery intima-media thickness; cIMT, carotid intima-media thickness; CVD, cardiovascular disease; IPD, individual-participant data; and NR, not reported.

all subgroups of trials investigated. The nonzero intercept—which indicates that a small proportion of the intervention effect on CVD risk bypasses cIMT—may be explained by pleiotropic effects; meaning that the intervention influences the clinical end point via multiple pathways. While effects of interventions on the extent of atherosclerosis may be captured by cIMT progression, any effects on other pathophysiological mechanisms related to CVD events, such as endogenous thrombogenesis and fibrinolysis,¹ may bypass cIMT progression and thereby lead to a nonzero intercept. Alternative pathways have been described for many major cardiovascular substance groups, including lipid-lowering medications (eg, statins,^{1,201,202} fibrates,²⁰³ niacin,²⁰⁴ resins,²⁰⁵ and omega-3 fatty acids²⁰⁶), antidiabetic medications (eg, AMP-activated protein kinase activators,²⁰⁷ thiazolidinediones,²⁰⁷ dipeptidyl peptidase-4 inhibitors,^{207,208} glucagon-like peptide-1 receptor agonists,^{207,208} sodium-glucose transport protein-2 inhibitors²⁰⁸), or antihypertensive medications (eg, β -blockers,²⁰⁹ calcium channel-inhibitors,^{210,211} angiotensin-II antagonists,²¹² angiotensin-converting enzyme inhibitors²¹²). Nevertheless, this finding does not negate the main result that an intervention effect on cIMT predicts the effect on CVD risk.

A major strength of our study is that we systematically collated and analyzed worldwide data on cIMT progression and CVD outcomes published up to February 2020. Access to patient-level data allowed us to include hitherto unpublished data and thereby reduce publication bias. Supplementing our analysis with published data enhanced generalizability and statistical power. Strengths of our meta-regression analysis include that it upheld randomization within trials, allowed for between-trials heterogeneity, made no distributional assumption about the true intervention effects on cIMT progression across trials (unlike standard bivariate random-effects meta-analysis), and improved precision by incorporating within-trial correlations of intervention effects on cIMT progression and CVD risk.

Our analysis also has limitations. First, our principal analysis combined trials of varying types of interventions. While we conducted a sensitivity analysis by medication class, further research is required to precisely quantify the differences in the surrogate value of cIMT by intervention type. Second, our analysis involved a broad range of types of trial populations. Whereas sensitivity analysis revealed no evidence for differential effects in the setting of primary versus secondary prevention trials, further study is needed on specific trial populations, such as patients with diabetes mellitus or chronic kidney disease. Third, the definition of the primary combined CVD end point varied across the included trials. However, the differences were relatively minor (see Table III in the Data Supplement), so we are confident that this does not constitute a major source of systematic bias. Last, while ultrasound scanning protocols may have differed across contributing trials, in particular those before consensus guidelines were available,²¹³

there was no evidence for effect modification by type of cIMT measure or baseline years of the trials.

Conclusions

In conclusion, effects of interventions on cIMT progression and on CVD risk are associated, endorsing the usefulness of cIMT progression as a surrogate marker in clinical trials. Using cIMT progression as a surrogate marker may be a useful tool to guide future development for cardiovascular drugs.

ARTICLE INFORMATION

Received February 19, 2020; accepted July 13, 2020.

This manuscript was sent to Steven Lloyd, Guest Editor, for review by expert referees, editorial decision, and final disposition.

Continuing medical education (CME) credit is available for this article. Go to <http://cme.ahajournals.org> to take the quiz.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.120.046361>.

Authors

Peter Willeit¹, MD, MPhil, PhD; Lena Tschiederer², DI, BSc, PhD; Elias Allara, MD; Kathrin Reuber, MSc; Lisa Seekircher, DI, Mag, BSc; Lu Gao, BSc, MSc; Ximing Liao, BSc, MSc, PhD; Eva Lonn, MD, MSc; Hertz C. Gerstein, MD, MSc; Salim Yusuf, MD, DPhil; Frank P. Brouwers, MD, PhD; Folkert W. Asselbergs, MD, PhD; Wiek van Gilst, PhD; Sigmund A. Anderssen, PhD; Diederick E. Grobbee, MD, PhD; John J.P. Kastelein, MD, PhD; Frank L.J. Visseren, MD; George Ntaios³, MD, MSc, PhD; Apostolos I. Hatzitolios, MD, PhD; Christos Savopoulos, MD, PhD; Pythia T. Nieuwkerk⁴, PhD; Erik Stroes, MD, PhD; Matthew Walters, MD; Peter Higgins, MD; Jesse Dawson, MD; Paolo Gresele, MD, PhD; Giuseppe Guglielmini⁵, PhD; Rino Migiacci, MD, PhD; Marat Ezhov, MD, PhD; Maya Safarova⁶, MD; Tatyana Balakhonova, MD, PhD; Eiichi Sato, MD; Mayuko Amaha, MD; Tsukasa Nakamura, MD, PhD; Kostas Kapellias, PhD; Lisa M. Jamieson, PhD; Michael Skilton⁷, PhD; James A. Blumenthal, PhD; Alan Hinderliter, MD; Andrew Sherwood⁸, PhD; Patrick J. Smith, PhD, MPH; Michiel A. van Agtmael⁹, MD, PhD; Peter Reiss, MD, PhD; Marit G.A. van Vonderen, MD, PhD; Stefan Kiechl¹⁰, MD; Gerhard Klingenschiedt¹¹, MD; Matthias Sitzer, MD; Coen D.A. Stehouwer¹², MD, PhD; Heiko Uthoff, MD, PhD; Zhi-Yong Zou, MD; Ana R. Cunha¹³, PhD; Mario F. Neves¹⁴, MD, PhD; Miles D. Witham, BMBCh, PhD; Hyun-Woong Park¹⁵, MD; Moo-Sik Lee, MD, PhD; Jang-Ho Bae, MD; Enrique Bernal¹⁶, MD, PhD; Kristian Wachtell, MD, PhD, DrMedSci; Sverre E. Kjeldsen¹⁷, MD, PhD; Michael H. Olsen, MD, PhD, DMSc; David Preiss¹⁸, PhD; Naveed Sattar, MD, PhD; Edith Beishuizen, MD; Menno V. Huismans, MD, PhD; Mark A. Espeland, PhD; Caroline Schmidt, PhD; Stefan Agewall, MD, PhD; Ercan Ok, MD; Gülay Aşçı, MD; Eric de Groot, MD, PhD; Muriel P.C. Grooteman, MD, PhD; Peter J. Blankstijn, MD; Michiel L. Bots, MD, PhD; Michael J. Sweeting, PhD; Simon G. Thompson, DSc; Matthias W. Lorenz, MD; For the PROG-IMT and the Proof-ATHERO Study Groups

Correspondence

Peter Willeit, MD, MPhil, PhD, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria. Email peter.willeit@i-med.ac.at

Affiliations

Department of Neurology, Medical University of Innsbruck, Austria (P.W., L.T., L.S., S.K., G.K.). Department of Public Health and Primary Care, University of Cambridge, United Kingdom (P.W., E.A., M.J.S., S.G.T.). National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, United Kingdom (E.A.). Department of Neurology, Goethe University, Frankfurt am Main, Germany (K.R., X.L., M. Sitzer, M.V.L.). MRC Biostatistics Unit, University of Cambridge, United Kingdom (L.G.). Department of Medicine and Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (E.L., H.C.G., S.Y.). Hamilton General Hospital, Ontario, Canada (E.L., H.C.G., S.Y.). Department of Cardiology, Haga Teaching Hospital, The Hague, The Netherlands (F.P.B.). Department of

Cardiology (F.W.A.), Julius Center for Health Sciences and Primary Care (D.E.G., M.L.B.), Department of Vascular Medicine (F.L.J.V.), and Department of Nephrology (P.J.B.), University Medical Center Utrecht, The Netherlands. Department of Experimental Cardiology, University Medical Center Groningen, The Netherlands (W.v.G.). Department of Sports Medicine, Norwegian School of Sports Sciences, Oslo, Norway (S.A.A.). Department of Vascular Medicine (J.J.P.K., E.S.), Department of Medical Psychology (P.T.N.), and Department of Global Health (P.R.), Academic Medical Centre, University of Amsterdam, The Netherlands. Department of Medicine, University of Thessaly, Larissa, Greece (G.N.). 1st Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Greece (A.I.H., C.S.). School of Medicine, Dentistry and Nursing (M.W.), Institute of Cardiovascular and Medical Sciences (P.H., J.D.), and BHF Glasgow Cardiovascular Research Centre (N.S.), University of Glasgow, United Kingdom. Division of Internal and Cardiovascular Medicine, Department of Medicine, University of Perugia, Italy (P.G., G.G.). Division of Internal Medicine, Cortona Hospital, Italy (R.M.). Laboratory of Lipid Disorders, National Medical Research Center of Cardiology, Moscow, Russia (M.E.), Atherosclerosis Department (M. Safarova), and Ultrasound Vascular Laboratory (T.B.), National Medical Research Center of Cardiology, Moscow, Russia. Division of Nephrology, Shinmatsudo Central General Hospital, Chiba, Japan (E.S., M.A., T.N.). Australian Research Centre for Population Oral Health, University of Adelaide, SA, Australia (K.K., L.M.J.). Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, NSW, Australia (M.Skilton). Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, (J.A.B., A.S., P.J.S.). Department of Medicine, University of North Carolina, Chapel Hill (A.H.). Department of Internal Medicine (M.A.v.A.) and Department of Nephrology (M.P.C.G.), Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. Amsterdam Institute for Global Health and Development, University of Amsterdam, The Netherlands (P.R.). Department of Internal Medicine, Medical Center Leeuwarden, The Netherlands (M.G.A.v.V.). VASCage GmbH, Research Centre on Vascular Ageing and Stroke, Innsbruck, Austria (S.K.). Department of Neurology, Klinikum Herford, Herford, Germany (M. Sitzer). Department of Internal Medicine and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, The Netherlands (C.D.A.S.). Department of Angiology, University Hospital Basel, Switzerland (H.U.). Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing, China (Z.-Y.Z.). Department of Clinical Medicine, State University of Rio de Janeiro, Brazil (A.R.C., M.F.N.). AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle-upon-Tyne Hospitals Trust, United Kingdom (M.D.W.). Department of Internal Medicine, Gyeongsang National University Hospital, Daejeon, South Korea (H.-W.P., M.-S.L.). Department of Preventive Medicine, Konyang University, Jinju, South Korea (M.-S.L.). Heart Center, Konyang University Hospital, Daejeon, South Korea (J.-H.B.). Department of Cardiology, Konyang University College of Medicine, Daejeon, South Korea (J.-H.B.). Infectious Diseases Unit, Reina Sofia Hospital, Murcia, Spain (E.B.). Department of Cardiology, Oslo University Hospital, Norway (K.W., S.E.K.). Department of Internal Medicine, Holbaek Hospital, University of Southern Denmark, Odense (M.H.O.). MRC Population Health Research Unit, Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, United Kingdom (D.P.). Department of Internal Medicine, HMC+ (Bronovo), The Hague, The Netherlands (E.B.). Department of Thrombosis and Hemostasis, Leiden University Medical Center, The Netherlands (M.V.H.). Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC (M.A.E.). Wallenberg Laboratory for Cardiovascular Research, University of Gothenburg, Sweden (C.S.). Oslo University Hospital Ullevål and Institute of Clinical Sciences, University of Oslo, Norway (S.A.). Nephrology Department, Ege University School of Medicine, Bornova-Izmir, Turkey (E.O., G.A.). Imagelabonline & Cardiovascular, Eindhoven and Lunten, the Netherlands (E.d.G.). Department of Health Sciences, University of Leicester, United Kingdom (M.J.S.).

Sources of Funding

This work was supported by the Austrian Science Fund (FWF; P 32488); the Dr-Johannes-and-Hertha-Tuba Foundation; the German Research Foundation (DFG Lo 1569/2-1 and DFG Lo 1569/2-3); and the excellence initiative "Competence Centers for Excellent Technologies" (COMET) of the Austrian Research Promotion Agency (FFG) "Research Center of Excellence in Vascular Ageing: Tyrol, VAS-Cage" (K-Project No. 843536), funded by Bundesministerium für Verkehr, Innovation und Technologie (BMVIT), Bundesministerium für Bildung, Wissenschaft und Forschung (BMWF), Wirtschaftsagentur Wien, and Standortagentur Tirol.

Disclosures

Dr Willeit reports grants from the German Research Foundation DFG, the Austrian Science Fund FWF, the Austrian Research Promotion Agency FFG and the

Dr-Johannes-and-Hertha-Tuba Foundation during the conduct of the study. Dr Tschiderer reports grants from the Dr-Johannes-and-Hertha-Tuba Foundation during the conduct of the study and nonfinancial support from Sanofi outside the submitted work. Dr Allara was supported by a National Institute for Health Research PhD studentship (NIHR BTRU-2014-10024) during the conduct of this study and reports support from EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant n° 116074 outside the submitted work. Mrs Seekircher reports nonfinancial support from Sanofi outside the submitted work. Dr Gerstein reports grants from Sanofi, Eli Lilly, Astra Zeneca, Boehringer Ingelheim, Novo Nordisk, Merck, and Abbott, and personal fees from Sanofi, Eli Lilly, Astra Zeneca, Boehringer Ingelheim, Abbott, Novo Nordisk, Merck, Janssen, Kowa Research Institute, and Cirijs outside the submitted work. Dr Stroes reports Lecturing/ad-boards fees paid to institution by Amgen, Sanofi-Regeneron, Novartis, Athera, Mylan unrelated to the present work. Dr Kapellas reports grants from the National Health and Medical Research Council during the conduct of the study. Dr Skilton reports grants from the National Health and Medical Research Council of Australia during the conduct of the study. Dr van Vonderen reports grants from Abbott International and Boehringer Ingelheim during the conduct of the study. Dr Kiehl reports grants from the Austrian Promotion Agency FFG outside the submitted work. Dr Klingenschmid reports nonfinancial support from Sanofi and Pfizer outside the submitted work. Dr Kjeldsen reports personal fees from Bayer, Merck KGaA, MSD, Sanofi, and Takeda outside the submitted work. Dr Olsen reports grants from the Novo Nordic Foundation outside the submitted work. Dr Sattar reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, NAPP Pharmaceuticals, Novo Nordisk, and Sanofi, and grants from Boehringer Ingelheim outside the submitted work. Dr Grooteman reports grants from the Dutch Kidney Foundation, Fresenius Medical Care Netherlands BV, Gambro Sweden, the Twiss Fund, and ZON MW during the conduct of the study. Dr Blankstijn reports grants from the European Commission and other financial activities from Medtronic, Baxter, and Braun outside the submitted work. Dr Bots reports grants from AstraZeneca outside the submitted work. Dr Sweeting reports grants from the German Research Foundation during the conduct of the study. Dr Thompson reports grants from the UK Medical Research Council, the British Heart Foundation, and the German Research Foundation DFG during the conduct of the study. Dr Lorenz reports grants from the German Research Foundation DFG during the conduct of the study. The other authors report no conflicts.

Supplemental Materials

Methods

Data Supplement Tables I–V

Data Supplement Figures I and II

Full list of the PROG-IMT and the Proof-ATHERO study groups and their affiliations
Reference 214

REFERENCES

- Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. *Nature*. 2011;473:317–325. doi: 10.1038/nature10146
- Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, et al; PROG-IMT Study Group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. *Lancet*. 2012;379:2053–2062. doi: 10.1016/S0140-6736(12)60441-3
- Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empiana JP, Etgen T, et al; PROG-IMT study group. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. *Eur J Prev Cardiol*. 2016;23:194–205. doi: 10.1177/2047487314560664
- Espeland MA, O'leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. *Curr Control Trials Cardiovasc Med*. 2005;6:3. doi: 10.1186/1468-6708-6-3
- Peters SA, den Ruijter HM, Grobbee DE, Bots ML. Results from a carotid intima-media thickness trial as a decision tool for launching a large-scale morbidity and mortality trial. *Circ Cardiovasc Imaging*. 2013;6:20–25. doi: 10.1161/CIRCIMAGING.112.978114
- Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe

- and carotid intima-media thickness. *N Engl J Med*. 2009;361:2113–2122. doi: 10.1056/NEJMoa0907569
7. Blumenthal RS, Michos ED. The HALTS trial—halting atherosclerosis or halted too early? *N Engl J Med*. 2009;361:2178–2180. doi: 10.1056/NEJMoa0908838
 8. Kastelein JJ, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. *N Engl J Med*. 2009;361:2180–2183. doi: 10.1056/NEJMoa0908841
 9. Goldberger ZD, Valle JA, Dandekar VK, Chan PS, Ko DT, Nallamothu BK. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. *Am Heart J*. 2010;160:701–714. doi: 10.1016/j.ahj.2010.06.029
 10. Costanzo P, Perrone-Filardi P, Vassallo E, Paolillo S, Cesarano P, Brevetti G, Chiariello M. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. *J Am Coll Cardiol*. 2010;56:2006–2020. doi: 10.1016/j.jacc.2010.05.059
 11. Bots ML, Taylor AJ, Kastelein JJ, Peters SA, den Ruijter HM, Tegeler CH, Baldassarre D, Stein JH, O'Leary DH, Revkin JH, et al. Rate of change in carotid intima-media thickness and vascular events: meta-analyses can not solve all the issues. A point of view. *J Hypertens*. 2012;30:1690–1696. doi: 10.1097/HJH.0b013e32835644dc
 12. Lorenz MW, Bickel H, Bots ML, Breteler MM, Catapano AL, Desvarieux M, Hedblad B, Iglstedder B, Johnsen SH, Juraska M, et al; PROG-IMT Study Group. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): rationale and design of a meta-analysis project. *Am Heart J*. 2010;159:730–736.e2. doi: 10.1016/j.ahj.2010.02.008
 13. White IR. Multivariate random-effects meta-analysis. *Stata Journal*. 2009;9:40–56. doi: 10.1177/1536867X0900900103
 14. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. *Stat Med*. 1997;16:1965–1982. doi: 10.1002/(sici)1097-0258(19970915)16:17<1965::aid-sim630>3.0.co;2-m
 15. Riley RD, Price MJ, Jackson D, Wardle M, Gueyffier F, Wang J, Staessen JA, White IR. Multivariate meta-analysis using individual participant data. *Res Synth Methods*. 2015;6:157–174. doi: 10.1002/jrsm.1129
 16. The ACAPS Group. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). *Control Clin Trials*. 1992;13:293–314. doi: 10.1016/0197-2456(92)90012-o
 17. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. *Circulation*. 1994;90:1679–1687. doi: 10.1161/01.cir.90.4.1679
 18. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, et al; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. *N Engl J Med*. 2011;364:1104–1115. doi: 10.1056/NEJMoa1010949
 19. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. *Arterioscler Thromb Vasc Biol*. 2013;33:393–399. doi: 10.1161/ATVBAHA.112.300346
 20. Higgins P, Walters MR, Murray HM, McArthur K, McConnachie A, Lees KR, Dawson J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. *Heart*. 2014;100:1085–1092. doi: 10.1136/heartjnl-2014-305683
 21. Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, Melnichenko AA, Balcells M, Edelman ER, Bobryshev YV. Anti-atherosclerotic therapy based on botanicals. *Recent Pat Cardiovasc Drug Discov*. 2013;8:56–66. doi: 10.2174/18722083113079990008
 22. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. *Circulation*. 2002;106:2055–2060. doi: 10.1161/01.cir.0000034508.55617.65
 23. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation*. 2004;110:3512–3517. doi: 10.1161/01.CIR.0000148955.19792.8D
 24. Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). *Cardiovasc Drugs Ther*. 2007;21:221–225. doi: 10.1007/s10557-007-6020-8
 25. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. *J Am Coll Cardiol*. 2010;55:2721–2726. doi: 10.1016/j.jacc.2010.03.017
 26. Laurent S, Boutouyrie P; Vascular Mechanism Collaboration. Dose-dependent arterial stiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. *Hypertension*. 2014;64:709–716. doi: 10.1161/HYPERTENSIONAHA.114.03282
 27. Salonen JT, Nyyssönen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Lakka TA, Rissanen T, Leskinen L, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. *J Intern Med*. 2000;248:377–386. doi: 10.1046/j.1365-2796.2000.00752.x
 28. Rissanen T, Voutilainen S, Nyyssönen K, Salonen R, Salonen JT. Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. *Arterioscler Thromb Vasc Biol*. 2000;20:2677–2681. doi: 10.1161/01.atv.20.12.2677
 29. Salonen RM, Nyyssönen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristomaa U, Lakka HM, et al; Antioxidant Supplementation in Atherosclerosis Prevention Study. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study. *Circulation*. 2003;107:947–953. doi: 10.1161/01.cir.0000050626.25057.51
 30. Smilde TJ, Trip MD, Wollersheim H, van Wissen S, Kastelein JJ, Stalenhoef AF. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia: the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. *Clin Drug Investig*. 2000;20:67–79. doi: 10.2165/00044011-200020020-00001
 31. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. *Lancet*. 2001;357:577–581. doi: 10.1016/s0140-6736(00)04053-8
 32. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. *J Am Coll Cardiol*. 2006;47:1108–1116. doi: 10.1016/j.jacc.2005.10.064
 33. Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, Teerlink T, van Dorp W, Stehouwer CD. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) study. *Arch Intern Med*. 2007;167:1262–1270. doi: 10.1001/archinte.167.12.1262
 34. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajlar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. *Kidney Int*. 2005;68:2230–2236. doi: 10.1111/j.1523-1755.2005.00680.x
 35. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. *Heart Vessels*. 2011;26:502–510. doi: 10.1007/s00380-010-0093-1
 36. Jalal DI, Decker E, Perrenoud L, Nowak KL, Bispham N, Mehta T, Smits G, You Z, Seals D, Chonchol M, et al. Vascular function and uric acid-lowering in stage 3 CKD. *J Am Soc Nephrol*. 2017;28:943–952. doi: 10.1681/ASN.2016050521
 37. Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M, Kendrick J, Jalal D. Examining the effects of uric acid-lowering on markers vascular calcification and CKD-MBD: A post-hoc analysis of a randomized clinical trial. *PLoS One*. 2018;13:e0205831. doi: 10.1371/journal.pone.0205831
 38. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering

- Asymptomatic Plaque Study (BCAPS). *Circulation*. 2001;103:1721–1726. doi: 10.1161/01.cir.103.13.1721
39. Bae JH, Bassenge E, Kim KY, Synn YC, Park KR, Schwemmer M. Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. *J Cardiovasc Pharmacol Ther*. 2004;9:185–192. doi: 10.1177/107424840400900306
 40. Hodis HN, Mack WJ, Dustin L, Maher PR, Azen SP, Detrano R, Selhub J, Alaupovic P, Liu CR, Liu CH, et al; BVAIT Research Group. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. *Stroke*. 2009;40:730–736. doi: 10.1161/STROKEAHA.108.526798
 41. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. *Am J Med*. 1996;101:627–634. doi: 10.1016/S0002-9343(96)00333-6
 42. Preiss D, Lloyd SM, Ford I, McMurray JJ, Holman RR, Welsh P, Fisher M, Packard CJ, Sattar N. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. *Lancet Diabetes Endocrinol*. 2014;2:116–124. doi: 10.1016/S2213-8587(13)70152-9
 43. Hong S, Nam M, Little BB, Paik S, Lee K, Woo J, Kim D, Kang J, Chun M, Park Y. Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-media thickness. *Heart Vessels*. 2019;34:1758–1768. doi: 10.1007/s00380-019-01421-1
 44. Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, et al; CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. *JAMA*. 2009;301:1131–1139. doi: 10.1001/jama.301.11.1131
 45. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. *Diabetes Care*. 2004;27:2887–2892. doi: 10.2337/diacare.27.12.2887
 46. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA*. 2006;296:2572–2581. doi: 10.1001/jama.296.21.joc60158
 47. Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, et al. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. *BMJ Open*. 2016;6:e008376. doi: 10.1136/bmjopen-2015-008376
 48. Lundby Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E, Gade-Rasmussen B, Glud C, Hedetoft C, Jarlov A, Jensen T, et al; CIMT Trial Group. Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. *Diabetes Obes Metab*. 2009;11:315–322. doi: 10.1111/j.1463-1326.2008.00959.x
 49. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, Mack WJ, Alaupovic P. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. *Circulation*. 1993;88:20–28. doi: 10.1161/01.cir.88.1.20
 50. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhorn DH, Hodis HN. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. *Circulation*. 1996;93:34–41. doi: 10.1161/01.cir.93.1.34
 51. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. *JAMA*. 1990;264:3013–3017. doi: 10.1001/jama.1990.03450230049028
 52. Penne EL, Blankstijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nubé MJ, van der Tweel I, Ter Wee PM; the CONTRAST study group. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRANsport Study (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. *Curr Control Trials Cardiovasc Med*. 2005;6:8. doi: 10.1186/1468-6708-6-8
 53. Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, et al; CONTRAST Investigators. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. *J Am Soc Nephrol*. 2012;23:1087–1096. doi: 10.1681/ASN.2011121140
 54. Cao AH, Wang J, Gao HQ, Zhang P, Qiu J. Beneficial clinical effects of grape seed proanthocyanidin extract on the progression of carotid atherosclerotic plaques. *J Geriatr Cardiol*. 2015;12:417–423. doi: 10.11909/j.issn.1671-5411.2015.04.014
 55. Yamasaki Y, Kim YS, Kawamori R. Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). *Cardiovasc Diabetol*. 2006;5:16. doi: 10.1186/1475-2840-5-16
 56. Katakami N, Kim YS, Kawamori R, Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. *Circulation*. 2010;121:2584–2591. doi: 10.1161/CIRCULATIONAHA.109.892414
 57. Hoogerbrugge N, de Groot E, de Heide LH, de Ridder MA, Birkenhäger JC, Stijnen T, Jansen H. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. *Neth J Med*. 2002;60:354–361.
 58. Ellingsen I, Seljeflot I, Arnesen H, Tonstad S. Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. *Nutr Metab Cardiovasc Dis*. 2009;19:8–14. doi: 10.1016/j.numecd.2008.01.006
 59. Asci G, Tz H, Ozkahya M, Duman S, Demirci MS, Cirit M, Sipahi S, Dheir H, Bozkurt D, Kircelli F, et al; EGE Study Group. The impact of membrane permeability and dialysate purity on cardiovascular outcomes. *J Am Soc Nephrol*. 2013;24:1014–1023. doi: 10.1681/ASN.2012090908
 60. Ok ES, Asci G, Toz H, Ritz E, Kircelli F, Sever MS, Ozkahya M, Sipahi S, Dheir H, Bozkurt D, et al. Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patients. *Clin Nephrol*. 2014;82:173–180. doi: 10.5414/cn108251
 61. Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, Budoff MJ, Henderson VW. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. *Menopause*. 2015;22:391–401. doi: 10.1097/GME.0000000000000343
 62. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, et al; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. *N Engl J Med*. 2016;374:1221–1231. doi: 10.1056/NEJMoa1505241
 63. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, et al; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. *Circulation*. 2002;106:2422–2427. doi: 10.1161/01.cir.0000039288.86470.dd
 64. Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. *Stroke*. 2002;33:572–577. doi: 10.1161/hs0202.102332
 65. Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, Caccia C, Johnson J, Waugh R, Sherwood A. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. *Arch Intern Med*. 2010;170:126–135. doi: 10.1001/archinternmed.2009.470
 66. Smith PJ, Blumenthal JA, Babyak MA, Craighead L, Welsh-Bohmer KA, Browndyke JN, Strauman TA, Sherwood A. Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. *Hypertension*. 2010;55:1331–1338. doi: 10.1161/HYPERTENSIONAHA.109.146795
 67. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med*. 2008;358:1431–1443. doi: 10.1056/NEJMoa0800742
 68. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Maher PR, Selzer RH, Liu CR, Liu CH, Azen SP; Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 2001;135:939–953. doi: 10.7326/0003-4819-135-11-200112040-00005

69. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005;366:1849–1861. doi: 10.1016/S0140-6736(05)67667-2
70. Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulthen LM, Salonen JT, Tuomainen TP, Yki-Järvinen H, Keech AC, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. *J Am Coll Cardiol*. 2008;52:2190–2197. doi: 10.1016/j.jacc.2008.09.049
71. Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. *Cardiovasc Drugs Ther*. 2012;26:349–358. doi: 10.1007/s10557-012-6395-z
72. Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). *Arterioscler Thromb Vasc Biol*. 2014;34:1298–1306. doi: 10.1161/ATVBAHA.113.302926
73. Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, Klop B, van Zeben J, van de Geijn GM, van der Meulen N, Birnie E, Prinzen L, Castro Cabezas M. Progression of subclinical atherosclerosis in subjects with rheumatoid arthritis and the metabolic syndrome. *Atherosclerosis*. 2018;271:84–91. doi: 10.1016/j.atherosclerosis.2018.02.019
74. Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, Klop B, Liem AH, van de Geijn GM, van der Meulen N, Birnie E, van der Zwan EM, van Zeben J, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis*. 2019;78:335–341. doi: 10.1136/annrheumdis-2018-214075
75. Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hancu N, Hanefeld M, Krum H, Ryden L, Smith S, et al; GRACE and ORIGIN Investigators. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). *Diabetes Care*. 2013;36:2466–2474. doi: 10.2337/dc12-2129
76. Gesele P, Miglicci R, Arosio E, Bonizzoni E, Minuz P, Violi F; NCX 4016-X-208 Study Group. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. *J Vasc Surg*. 2012;56:1622–8, 1628.e1. doi: 10.1016/j.jvs.2012.05.064
77. Held C, Sumner G, Sheridan P, McQueen M, Smith S, Dagenais G, Yusuf S, Lonn E. Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). *Vasc Med*. 2008;13:245–253. doi: 10.1177/1358863X08092102
78. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E; Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin JAMA. 1998;280:605–613. doi: 10.1001/jama.280.7.605
79. Byington RP, Furberg CD, Herrington DM, Herd JA, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland CC, et al; Heart and Estrogen/Progestin Replacement Study Research Group. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. *Arterioscler Thromb Vasc Biol*. 2002;22:1692–1697. doi: 10.1161/01.atv.0000033514.79653.04
80. Anderssen SA, Hjelstuen AK, Hjermann I, Bjerkan K, Holme I. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. *Atherosclerosis*. 2005;178:387–397. doi: 10.1016/j.atherosclerosis.2004.08.033
81. Simon A, Gariépy J, Moysé D, Levenson J. Differential effects of nifedipine and co-amlozide on the progression of early carotid wall changes. *Circulation*. 2001;103:2949–2954. doi: 10.1161/01.cir.103.24.2949
82. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet*. 2000;356:366–372. doi: 10.1016/S0140-6736(00)02527-7
83. Taddei S, Ghiadoni L, Salvetti A. Current treatment of patients with hypertension: therapeutic implications of INSIGHT. *Drugs*. 2003;63:1435–1444. doi: 10.2165/00003495-200363140-00001
84. Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa K, et al; J-STARs Collaborators. The Japan Statin Treatment Against Recurrent Stroke (J-STARs): a multicenter, randomized, open-label, parallel-group study. *EBioMedicine*. 2015;2:1071–1078. doi: 10.1016/j.ebiom.2015.08.006
85. Toyoda K, Minematsu K, Yasaka M, Nagai Y, Hosomi N, Origasa H, Kitagawa K, Uchiyama S, Koga M, Matsumoto M; J-STARs Investigators. The Japan Statin Treatment Against Recurrent Stroke (J-STARs) Echo Study: rationale and trial protocol. *J Stroke Cerebrovasc Dis*. 2017;26:595–599. doi: 10.1016/j.jstrokecerebrovasdis.2016.11.113
86. Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, Aoki S, Nezu T, Hosomi N, Kagimura T, Origasa H, et al; J-STARs Investigators. Long-term effect of pravastatin on carotid intima-media complex thickness: the J-STARs Echo Study (Japan Statin Treatment Against Recurrent Stroke). *Stroke*. 2018;49:107–113. doi: 10.1161/STROKEAHA.117.018387
87. Wada S, Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, Aoki S, Nezu T, Hosomi N, Kagimura T, et al; Japan Statin Treatment Against Recurrent Stroke (J-STARs) Echo Study Collaborators. Factors associated with intima-media complex thickness of the common carotid artery in Japanese noncardioembolic stroke patients with hyperlipidemia: the J-STARs Echo Study. *J Atheroscler Thromb*. 2018;25:359–373. doi: 10.5551/jat.41533
88. Wada S, Koga M, Minematsu K, Toyoda K, Suzuki R, Kagimura T, Nagai Y, Aoki S, Nezu T, Hosomi N, et al. Baseline carotid intima-media thickness and stroke recurrence during secondary prevention with pravastatin. *Stroke*. 2019;50:1586–1589. doi: 10.1161/STROKEAHA.119.024968
89. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, et al; Justification for Atherosclerosis Regression Treatment (JART) Investigators. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study. *Circ J*. 2012;76:221–229. doi: 10.1253/circj.11-0887
90. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. *Circulation*. 1995;92:1758–1764. doi: 10.1161/01.cir.92.7.1758
91. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. *Ann Intern Med*. 2014;161:249–260. doi: 10.7326/M14-0353
92. Fulton RL, McMurdo ME, Hill A, Abboud RJ, Arnold GP, Struthers AD, Khan F, Vermeer C, Knapen MH, Drummen NE, et al. Effect of vitamin K on vascular health and physical function in older people with vascular disease—a randomized controlled trial. *J Nutr Health Aging*. 2016;20:325–333. doi: 10.1007/s12603-015-0619-4
93. Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, Kosugi K, Hori M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. *Diabetologia*. 2004;47:1906–1913. doi: 10.1007/s00125-004-1547-8
94. Koyasu M, Ishii H, Watarai M, Takemoto K, Inden Y, Takeshita K, Amano T, Yoshikawa D, Matsubara T, Murohara T. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. *Clin Ther*. 2010;32:1610–1617. doi: 10.1016/j.clinthera.2010.07.015
95. Ludwig M, Stapff M, Ribeiro A, Fritschka E, Tholl U, Smith RD, Stumpe KO. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. *Clin Ther*. 2002;24:1175–1193. doi: 10.1016/s0149-2918(02)80028-5
96. Olsen MH, Fossum E, Høieggan A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. *J Hypertens*. 2005;23:891–898. doi: 10.1097/01.hjh.0000163160.60234.15

97. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H; LIPID Trial Research Group. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID atherosclerosis substudy. *Circulation*. 1998;97:1784–1790. doi: 10.1161/01.cir.97.18.1784
98. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. *Am J Cardiol*. 1995;76:474–479. doi: 10.1016/S0002-9149(99)80133-7
99. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med*. 1998;339:1349–1357. doi: 10.1056/NEJM199811053391902
100. Watts GF. Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or hormones for courses? *Eur Heart J*. 2004;25:716–719. doi: 10.1016/j.ehj.2003.12.024
101. Luijckx P, Bouma BJ, Vriend JW, Groenink M, Vliegen HW, de Groot E, Pieper PG, van Dijk AP, Sieswerda GT, Veen G, et al. Rationale and design of a trial on the effect of high dose statins on cardiovascular risk in adults after successful coarctation repair. *Contemp Clin Trials*. 2012;33:410–416. doi: 10.1016/j.cct.2011.11.011
102. Luijckx P, Bouma BJ, Vriend JW, Groenink M, Vliegen HW, de Groot E, Pieper PG, van Dijk AP, Sieswerda GT, Konings TC, et al. Beneficial effect of high dose statins on the vascular wall in patients with repaired aortic coarctation? *Int J Cardiol*. 2014;176:40–47. doi: 10.1016/j.ijcard.2014.06.016
103. Blankenhorn DH, Azen SP, Krams DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI, et al; MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). *Ann Intern Med*. 1993;119:969–976. doi: 10.7326/0003-4819-119-10-199311150-00002
104. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. *Ann Intern Med*. 1996;124:548–556. doi: 10.7326/0003-4819-124-6-199603150-00002
105. Magliano D, McNeil J, Branley P, Shiel L, Demos L, Wolfe R, Kotsopoulos D, McGrath B. The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. *Eur J Cardiovasc Prev Rehabil*. 2006;13:341–347. doi: 10.1097/01.hjr.0000219108.10167.46
106. Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters-Sengers H, de Maar EF, van der Pant KA, de Vries AP, Sanders JS, Zwinderman A, et al. Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial. *Am J Transplant*. 2017;17:1020–1030. doi: 10.1111/ajt.14048
107. van Dijk M, van Roon AM, Said MY, Bemelman FJ, Homan van der Heide JJ, de Fijter HW, de Vries APJ, Bakker SJL, Sanders JSF. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial. *Transpl Int*. 2018;31:1380–1390. doi: 10.1111/tri.13322
108. van Vonderen MGA, Hassink EAM, van Agtmael MA, Stehouwer CDA, Danner SA, Reiss P, Smulders Y. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. *J Infect Dis*. 2009;199:1186–1194. doi: 10.1086/597475
109. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, Sutinen J, Ristola M, Danner SA, Reiss P. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. *AIDS*. 2009;23:1367–1376. doi: 10.1097/QAD.0b013e32832c4947
110. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. *JAMA*. 2007;297:1344–1353. doi: 10.1001/jama.297.12.1344
111. Cunha AR, D'El-Rei J, Medeiros F, Umbelino B, Oigman W, Touyz RM, Neves MF. Oral magnesium supplementation improves endothelial function and attenuates subclinical atherosclerosis in thiazide-treated hypertensive women. *J Hypertens*. 2017;35:89–97. doi: 10.1097/HJH.0000000000001129
112. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. *JAMA*. 1996;276:785–791. doi: 10.1001/jama.1996.03540100029024
113. Valensi P, Baguet J-P, Asmar R, Nisse-Durgeat S, Mallion J-M. Effect of candesartan cilexetil on carotid intima-media thickness in hypertensive type 2 diabetic patients. MITEC study: design and baseline characteristics. *Br J Diabetes Vasc Dis*. 2007;7:18–24. doi: 10.1177/14746514070070010401
114. Baguet JP, Asmar R, Valensi P, Nisse-Durgeat S, Mallion JM. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. *Vasc Health Risk Manag*. 2009;5:175–183. doi: 10.2147/VHRM.S3409
115. Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. *J Clin Endocrinol Metab*. 2012;97:4769–4779. doi: 10.1210/jc.2012-2794
116. Masiá M, Bernal E, Padilla S, García N, Escribano JC, Martínez E, Gutiérrez F. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. *J Antimicrob Chemother*. 2009;64:589–598. doi: 10.1093/jac/dkp250
117. Mitsuhashi N, Tanaka Y, Kubo S, Ogawa S, Hayashi C, Uchino H, Shimizu T, Watada H, Kawasumi M, Onuma T, et al. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. *Endocr J*. 2004;51:545–550. doi: 10.1507/endocrj.51.545
118. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A. Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. *Eur Neurol*. 2013;69:309–316. doi: 10.1159/000346427
119. Ishigaki Y, Kono S, Katagiri H, Oka Y, Oikawa S; NTPP investigators. Elevation of HDL-C in response to statin treatment is involved in the regression of carotid atherosclerosis. *J Atheroscler Thromb*. 2014;21:1055–1065. doi: 10.5551/jat.22095
120. Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, Koide H. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. *Kidney Blood Press Res*. 2004;27:121–126. doi: 10.1159/000077536
121. Ntaios G, Savopoulos C, Karamitsos D, Economou I, Destanis E, Chrysogonidis I, Pidonia I, Zebekakis P, Polatides C, Sion M, et al. The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial. *Int J Cardiol*. 2010;143:16–19. doi: 10.1016/j.ijcard.2009.01.023
122. Bots ML, Evans GW, Riley W, Meijer R, McBride KH, Paskett ED, Helmond FA, Grobbee DE; OPAL Investigators. The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. *Control Clin Trials*. 2003;24:752–775. doi: 10.1016/S0197-2456(03)00096-5
123. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE; OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. *Eur Heart J*. 2006;27:746–755. doi: 10.1093/eurheartj/ehi695
124. MacMahon S, Sharpe N, Gamble G, Clague A, Murchu CN, Clark T, Hart H, Scott J, White H. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. *J Am Coll Cardiol*. 2000;36:438–443. doi: 10.1016/S0735-1097(00)00736-1
125. Ikeda K, Takahashi T, Yamada H, Matsui K, Sawada T, Nakamura T, Matsubara H; (for the PEACE Investigators). Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). *Eur J Prev Cardiol*. 2013;20:1069–1079. doi: 10.1177/2047487312451539
126. Bousser MG, Amarencu P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoue A, et al; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. *Lancet*. 2011;377:2013–2022. doi: 10.1016/S0140-6736(11)60600-4

127. Bots ML, Ford I, Lloyd SM, Laurent S, Touboul PJ, Hennerici MG; Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack Vascular Ultrasound Study Investigators. Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial. *Stroke*. 2014;45:2348–2353. doi: 10.1161/STROKEAHA.114.004775
128. Kapellas K, Maple-Brown LJ, Jamieson LM, Do LG, O'Dea K, Brown A, Cai TY, Anstey NM, Sullivan DR, Wang H, et al. Effect of periodontal therapy on arterial structure and function among aboriginal Australians: a randomized, controlled trial. *Hypertension*. 2014;64:702–708. doi: 10.1161/HYPERTENSIONAHA.114.03359
129. Angerer P, Kothny W, Störk S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. *J Am Coll Cardiol*. 2000;36:1789–1796. doi: 10.1016/s0735-1097(00)00969-4
130. Zanchetti A, Crepaldi G, Bond MG, Gallus GV, Veglia F, Ventura A, Mancia G, Baggio G, Sampieri L, Rubba P, et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. *J Hypertens*. 2001;19:79–88. doi: 10.1097/00004872-200101000-00011
131. Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G, Ventura A, Baggio G, Sampieri L, Rubba P, et al; PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS—a randomized double-blind trial. *Stroke*. 2004;35:2807–2812. doi: 10.1161/01.STR.0000147041.00840.59
132. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. *Am J Cardiol*. 1994;73:1133–1134. doi: 10.1016/0002-9149(94)90297-6
133. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol*. 1995;75:455–459. doi: 10.1016/s0002-9149(99)80580-3
134. Byington RP, Furberg CD, Crouse JR, Espeland MA, Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol*. 1995;76:54C–59C. doi: 10.1016/S0002-9149(99)80471-8
135. Bhatt DL, Chew DP, Grines C, Mukherjee D, Leeser M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhilb S, et al. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR study. *Am Heart J*. 2007;154:137–143. doi: 10.1016/j.ahj.2007.03.029
136. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368:1279–1290. doi: 10.1056/NEJMoa1200303
137. Sala-Vila A, Romero-Mamani ES, Gilabert R, Núñez I, de la Torre R, Corella D, Ruiz-Gutiérrez V, López-Sabater MC, Pintó X, Rekondo J, et al. Changes in ultrasound-assessed carotid intima-media thickness and plaque with a Mediterranean diet: a substudy of the PREDIMED trial. *Arterioscler Thromb Vasc Biol*. 2014;34:439–445. doi: 10.1161/ATVBAHA.113.302327
138. Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijs HJ, van Gilst WH. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of Renal and Vascular Endstage Disease Intervention Trial [PREVEND IT]). *Am J Cardiol*. 2000;86:635–638. doi: 10.1016/s0002-9149(00)01042-0
139. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. *Circulation*. 2004;110:2809–2816. doi: 10.1161/01.CIR.0000146378.65439.7A
140. Asselbergs FW, van Roon AM, Hillege HL, de Jong PE, Gans RO, Smit AJ, van Gilst WH; PREVEND IT Investigators. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. *Stroke*. 2005;36:649–653. doi: 10.1161/01.STR.0000155731.92786.e9
141. Brouwers FP, Asselbergs FW, Hillege HL, de Boer RA, Gansevoort RT, van Veldhuisen DJ, van Gilst WH. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). *Am Heart J*. 2011;161:1171–1178. doi: 10.1016/j.ahj.2011.03.028
142. Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). *Am J Cardiol*. 1997;80:1087–1090. doi: 10.1016/s0002-9149(97)00611-5
143. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVEND Investigators. *Circulation*. 2000;102:1503–1510. doi: 10.1161/01.cir.102.13.1503
144. Kaku K, Daida H, Kashiwagi A, Yamashina A, Yamazaki T, Momomura S, Iwase T, Yamasaki Y, Nagatsuka K, Kitagawa K, et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. *Curr Med Res Opin*. 2009;25:2925–2932. doi: 10.1185/03007990903328124
145. Yamasaki Y, Katakami N, Furukado S, Kitagawa K, Nagatsuka K, Kashiwagi A, Daida H, Kawamori R, Kaku K. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. *J Atheroscler Thromb*. 2010;17:1132–1140. doi: 10.5551/jat.4663
146. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, et al; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. *N Engl J Med*. 2007;356:1620–1630. doi: 10.1056/NEJMoa071359
147. Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML; RADIANCE 1 and 2 Study Investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. *Curr Med Res Opin*. 2007;23:885–894. doi: 10.1185/030079907x182121
148. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, et al; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. *Lancet*. 2007;370:153–160. doi: 10.1016/S0140-6736(07)61088-5
149. Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. *J Intern Med*. 2007;261:293–305. doi: 10.1111/j.1365-2796.2007.01767.x
150. de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Akerstaff RA, Bruschke AV. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. *Am J Cardiol*. 1995;76:40C–46C. doi: 10.1016/S0002-9149(99)80469-X
151. de Groot E, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Akerstaff RG, van der Steen AF, Bom N, Lie KI, Bruschke AV. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). *J Am Coll Cardiol*. 1998;31:1561–1567. doi: 10.1016/s0735-1097(98)00170-3
152. Petrie JR, Chaturvedi N, Ford I, Hramiak I, Hughes AD, Jenkins AJ, E Klein B, Klein R, Ooi TC, Rossing P, et al; REMOVAL Trial Team. Metformin in adults with type 1 diabetes: design and methods of REDucing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. *Diabetes Obes Metab*. 2017;19:509–516. doi: 10.1111/dom.12840
153. Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2017;5:597–609. doi: 10.1016/S2213-8587(17)30194-8
154. Agewall S, Fagerberg B, Berglund G, Schmidt C, Wendelhag I, Wikstrand J; Risk Factor Intervention Study Group, Sweden. Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media

- thickness and clinical outcome during 6 years of follow-up. *J Intern Med*. 2001;249:305–314. doi: 10.1046/j.1365-2796.2001.00818.x
155. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. *JAMA*. 2008;299:1678–1689. doi: 10.1001/jama.299.14.1678
156. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. *J Am Coll Cardiol*. 2008;52:2198–2205. doi: 10.1016/j.jacc.2008.10.031
157. Weir MR, Yeh F, Silverman A, Devereux RB, Galloway JM, Henderson JA, Howard WJ, Russell M, Wilson C, Ratner R, et al. Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. *J Clin Hypertens (Greenwich)*. 2009;11:540–548. doi: 10.1111/j.1751-7176.2009.00121.x
158. Angerer P, Kothny W, Störk S, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. *Cardiovasc Res*. 2002;54:183–190. doi: 10.1016/s0008-6363(02)00229-8
159. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1999;130:554–562. doi: 10.7326/0003-4819-130-7-199904060-00003
160. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). *Circulation*. 2001;103:919–925. doi: 10.1161/01.cir.103.7.919
161. Mayer-Berger W, Simic D, Mahmoodzad J, Burtcher R, Kohlmeyer M, Schwitala B, Redaelli M. Efficacy of a long-term secondary prevention programme following inpatient cardiovascular rehabilitation on risk and health-related quality of life in a low-education cohort: a randomized controlled study. *Eur J Prev Cardiol*. 2014;21:145–152. doi: 10.1177/2047487312465526
162. Elkeles RS, Diamond JR, Poulter C, Dhanji S, Nicolaidis AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. *Diabetes Care*. 1998;21:641–648. doi: 10.2337/diacare.21.4.641
163. Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, et al; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial. Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). *J Atheroscler Thromb*. 2013;20:893–902. doi: 10.5551/jat.18333
164. Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). *Diabetes Care*. 2016;39:139–148. doi: 10.2337/dc15-0781
165. Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): a randomized controlled trial. *Diabetes Care*. 2016;39:455–464. doi: 10.2337/dc15-2145
166. Mita T, Katakami N, Shiraiwa T, Yoshii H, Goshio M, Shimomura I, Watada H; Sitagliptin Preventive Study of Intima-media Thickness Evaluation (SPIKE) Trial. Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation. *J Diabetes Investig*. 2017;8:254–255. doi: 10.1111/jdi.12559
167. Katakami N, Mita T, Irie Y, Takahara M, Matsuoka TA, Goshio M, Watada H, Shimomura I; Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE) Collaborators. Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). *Cardiovasc Diabetol*. 2018;17:24. doi: 10.1186/s12933-018-0666-3
168. Lonn EM, Gerstein HC, Sheridan P, Smith S, Diaz R, Mohan V, Bosch J, Yusuf S, Dagenais GR; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) and STARR Investigators. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (Study of Atherosclerosis with Ramipril and Rosiglitazone). *J Am Coll Cardiol*. 2009;53:2028–2035. doi: 10.1016/j.jacc.2008.12.072
169. Chaiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA*. 2003;290:486–494. doi: 10.1001/jama.290.4.486
170. Hanefeld M, Chaiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. *Stroke*. 2004;35:1073–1078. doi: 10.1161/01.STR.0000125864.01546.f2
171. Safarova MS, Trukhacheva EP, Ezhov MV, Afanas'eva OI, Afanas'eva MI, Tripoten' MI, Liakishev AA, Pokrovskii SN. [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. *Kardiologiia*. 2011;51:9–16.
172. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. *Circulation*. 2001;103:1390–1395. doi: 10.1161/01.cir.103.10.1390
173. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. *Circulation*. 2002;106:2428–2433. doi: 10.1161/01.cir.0000036748.26775.8d
174. Spring S, Simon R, van der Loo B, Kovacevic T, Brookes C, Rousson V, Amann-Vesti B, Koppensteiner R. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. *Thromb Haemost*. 2008;99:182–189. doi: 10.1160/TH07-04-0265
175. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. *JAMA*. 2014;312:380–389. doi: 10.1001/jama.2014.8334
176. Stanton AV, Chapman JN, Mayet J, Sever PS, Poulter NR, Hughes AD, Thom SA. Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. *Clin Sci (Lond)*. 2001;101:455–464. doi: 10.1042/cs1010455
177. Hodis HN, Mack WJ, Zheng L, Li Y, Torres M, Sevilla D, Stewart Y, Hollen B, Garcia K, Alaupovic P, et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. *Diabetes Care*. 2006;29:1545–1553. doi: 10.2337/dc05-2462
178. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, Pencina KM, Vita J, Dzekov C, Mazer NA, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. *JAMA*. 2015;314:570–581. doi: 10.1001/jama.2015.8881
179. Xiang AH, Peters RK, Kjos SL, Ochoa C, Marroquin A, Goico J, Tan S, Wang C, Azen SP, Liu CR, et al. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. *J Clin Endocrinol Metab*. 2005;90:1986–1991. doi: 10.1210/jc.2004-1685
180. Tasić IS, Mijalković D, Djordjević D, Lović B, Janković D, Miladinović-Tasić N, Lović M. [Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients]. *Srp Arh Celok Lek*. 2006;134:106–113. doi: 10.2298/sarh0604106t
181. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevastian A, Liu CR, Liu CH, Huang J, Selzer RH, Azen SP; VEAPS Research Group. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). *Circulation*. 2002;106:1453–1459. doi: 10.1161/01.cir.0000029092.99946.08
182. Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. *J Hypertens*. 1997;15:1337–1344. doi: 10.1097/00004872-199715110-00019
183. Zanchetti A, Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone

- on carotid intima-media thickness. *J Hypertens*. 1998;16:1667–1676. doi: 10.1097/00004872-199816110-00014
184. Mourer JS, de Koning EJ, van Zwet EW, Mallat MJ, Rabelink TJ, de Fijter JW. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. *Transplantation*. 2013;96:49–57. doi: 10.1097/TP.0b013e3182958552
 185. Nieuwkerk PT, Nierman MC, Vissers MN, Locadia M, Greggers-Peusch P, Knape LP, Kastelein JJ, Sprangers MA, de Haes HC, Stroes ES. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. *Am J Cardiol*. 2012;110:666–672. doi: 10.1016/j.amjcard.2012.04.045
 186. Hodis HN, Mack WJ, Kono N, Azen SP, Shoupe D, Hwang-Levine J, Petitti D, Whitfield-Maxwell L, Yan M, Franke AA, et al; Women's Isoflavone Soy Health Research Group. Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial. *Stroke*. 2011;42:3168–3175. doi: 10.1161/STROKEAHA.111.620831
 187. Yang M, Luo Y, Liu T, Zhong X, Yan J, Huang Q, Tao J, He Q, Guo M, Hu Y. The effect of puerarin on carotid intima-media thickness in patients with active rheumatoid arthritis: a randomized controlled trial. *Clin Ther*. 2018;40:1752–1764.e1. doi: 10.1016/j.clinthera.2018.08.014
 188. Yun P, Du AM, Chen XJ, Liu JC, Xiao H. Effect of acarbose on long-term prognosis in acute coronary syndromes patients with newly diagnosed impaired glucose tolerance. *J Diabetes Res*. 2016;2016:1602083. doi: 10.1155/2016/1602083
 189. Zou ZY, Xu XR, Lin XM, Zhang HB, Xiao X, Ouyang L, Huang YM, Wang X, Liu YQ. Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. *Br J Nutr*. 2014;111:474–480. doi: 10.1017/S0007114513002730
 190. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engström G, Evans GW, de Graaf J, Grobbee DE, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. *JAMA*. 2012;308:796–803. doi: 10.1001/jama.2012.9630
 191. Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. *N Engl J Med*. 2011;365:213–221. doi: 10.1056/NEJMoa1012592
 192. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation*. 2007;115:459–467. doi: 10.1161/CIRCULATIONAHA.106.628875
 193. Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, Kavousi M, Dörr M, Stensland E, Ducimetiere P, et al. Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. *Diabetes Care*. 2015;38:1921–1929. doi: 10.2337/dc14-2732
 194. Lorenz MW, Gao L, Ziegelbauer K, Norata GD, Empana JP, Schmidtman I, Lin H-J, McLachlan S, Bokemark L, Ronkainen K, et al. Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration. *PLoS One*. 2018;13:e0191172. doi: 10.1371/journal.pone.0191172
 195. Bots ML, Evans GW, Tegeler CH, Meijer R. Carotid intima-media thickness measurements: relations with atherosclerosis, risk of cardiovascular disease and application in randomized controlled trials. *Chin Med J (Engl)*. 2016;129:215–226. doi: 10.4103/0366-6999.173500
 196. Peters SAE, Grobbee DE, Bots ML. Carotid intima-media thickness: a suitable alternative for cardiovascular risk as outcome? *Eur J Cardiovasc Prev Rehabil*. 2011;18:167–174. doi: 10.1177/1741826710389400
 197. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. *Circulation*. 1986;74:1399–1406. doi: 10.1161/01.cir.74.6.1399
 198. Dogan S, Plantinga Y, Crouse JR III, Evans GW, Raichlen JS, O'Leary DH, Palmer MK, Grobbee DE, Bots ML; METEOR Study Group. Algorithms to measure carotid intima-media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect. *J Hypertens*. 2011;29:2181–2193. doi: 10.1097/HJH.0b013e32834b0eba
 199. Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). *Cerebrovasc Dis*. 2012;34:290–296. doi: 10.1159/000343145
 200. Huang R, Mills K, Romero J, Li Y, Hu Z, Cao Y, Huang H, Xu Y, Jiang L. Comparative effects of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on carotid artery intima-media thickness progression: a network meta-analysis. *Cardiovasc Diabetol*. 2019;18:14. doi: 10.1186/s12933-019-0817-1
 201. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. *Trends Mol Med*. 2008;14:37–44. doi: 10.1016/j.molmed.2007.11.004
 202. Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. *Br J Pharmacol*. 2017;174:3973–3985. doi: 10.1111/bph.13805
 203. Chinetti-Gbaguidi G, Fruchart JC, Staels B. Pleiotropic effects of fibrates. *Curr Atheroscler Rep*. 2005;7:396–401. doi: 10.1007/s11883-005-0053-x
 204. Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. *Curr Vasc Pharmacol*. 2011;9:385–400. doi: 10.2174/15701611796197279
 205. Yamaoka-Tojo M, Tojo T, Izumi T. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. *Curr Vasc Pharmacol*. 2008;6:271–281. doi: 10.2174/15701610878509698
 206. Papazafropoulou AK, Kardara MS, Pappas SI. Pleiotropic effects of omega-3 fatty acids. *Recent Pat Endocr Metab Immune Drug Discov*. 2012;6:40–46. doi: 10.2174/187221412799015254
 207. Scheen AJ, Esser N, Paquot N. Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. *Diabetes Metab*. 2015;41:183–194. doi: 10.1016/j.diabet.2015.02.003
 208. Desouza CV, Gupta N, Patel A. Cardiometabolic effects of a new class of antidiabetic agents. *Clin Ther*. 2015;37:1178–1194. doi: 10.1016/j.clinthera.2015.02.016
 209. Yun S, Vincelette ND, Abraham I. Cardioprotective role of β -blockers and angiotensin antagonists in early-onset anthracycline-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. *Postgrad Med J*. 2015;91:627–633. doi: 10.1136/postgradmedj-2015-133535
 210. Schulman IH, Zachariah M, Raji L. Calcium channel blockers, endothelial dysfunction, and combination therapy. *Aging Clin Exp Res*. 2005;17(4 Suppl):40–45.
 211. Preston Mason R. Pleiotropic effects of calcium channel blockers. *Curr Hypertens Rep*. 2012;14:293–303. doi: 10.1007/s11906-012-0269-4
 212. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet*. 2010;375:906–915. doi: 10.1016/S0140-6736(10)60235-8
 213. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Kownator S, et al; Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference. Mannheim intima-media thickness consensus. *Cerebrovasc Dis*. 2004;18:346–349. doi: 10.1159/000081812
 214. Bujkiewicz S, Thompson JR, Spata E, Abrams KR. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate end points. *Stat Methods Med Res*. 2017;26:2287–2318. doi: 10.1177/0962280215597260